The Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII) took place in Madrid, Spain, on June 26-29, 2016, and was attended by >200 delegates from 31 countries. The present Progress Report provides an update on experimental and clinical results for drugs presented at the Conference. Compounds for which summary data are presented include an AED approved in 2016 (brivaracetam), 12 drugs in phase I-III clinical development (adenosine, allopregnanolone, bumetanide, cannabidiol, cannabidivarin, 2-deoxy-D-glucose, everolimus, fenfluramine, huperzine A, minocycline, SAGE-217, and valnoctamide) and 6 compounds or classes of compounds for which only preclinical data are available (bumetanide derivatives, sec-butylpropylacetamide, FV-082, 1OP-2198, NAX 810-2, and SAGE-689). Overall, the results presented at the Conference show that considerable efforts are ongoing into discovery and development of AEDs with potentially improved therapeutic profiles compared with existing agents. Many of the drugs discussed in this report show innovative mechanisms of action and many have shown promising results in patients with pharmacoresistant epilepsies, including previously neglected rare and severe epilepsy syndromes. KEY WORDS: Antiepileptic drugs, Drug development, Epilepsy, Epilepsy targets.
Introduction and rationale for development
The purine ribonucleoside adenosine is an endogenous anticonvulsant and seizure terminator in the brain. 4 In addition, adenosine affects epigenetic mechanisms thought to be instrumental in epileptogenesis. 5 Therefore, increasing adenosine levels represent a potentially valuable strategy to prevent not only seizures and associated comorbidities but also the progression of epilepsy. [5] [6] [7] [8] In the adult brain, the availability of adenosine is largely under the control of metabolic clearance through adenosine kinase (ADK), a ribokinase expressed predominantly in astrocytes. 9 We and others have shown that increased ADK is a pathologic hallmark of the epileptic brain and linked intricately to epileptogenesis and disease progression. 10, 11 High levels of ADK result in reduced adenosine levels, which leads to lower seizure thresholds and increased DNA methylation. 5 Changes in the DNA methylome are thought to contribute to epileptogenesis and disease progression. We provided robust evidence in different experimental settings that the transient therapeutic augmentation of adenosine (e.g., locally via adenosine releasing silk, as discussed in the EILAT XII Progress Report 3 ) prevents epileptogenesis in etiologically relevant rodent models of temporal lobe epilepsy. The proven antiepileptogenic effects of adenosine are based on an epigenetic mechanism, whereby a transient dose of adenosine triggers lasting changes in the DNA methylome. 5 ADK inhibitors effectively raise adenosine levels and therefore were considered for clinical translation earlier in this century for the treatment of seizures, chronic pain, and chronic inflammatory conditions. 9 Although highly efficient therapeutically, the chronic use of those agents is limited by adverse effects. The existence of a nuclear isoform of ADK with specific epigenetic functions 5 provides a rationale for the development of small molecule inhibitors that preferentially act on the nuclear isoform ADK-L in order to capitalize on epigenetic therapeutic effects while reducing adenosine receptor-mediated effects controlled by the cytoplasmic isoform ADK-S.
Pharmacology
Adenosine is both an endogenous metabolite as well as a ligand of the G protein-coupled adenosine receptors (A 1 , A 2A , A 2B , and A 3 ). 4 As metabolite, adenosine regulates transmethylation reactions, including DNA methylation, through mass action. 5 Adenosine metabolism in the brain is largely under the control of the astrocyte-based ribokinase ADK. 9 
Anticonvulsant and antiepileptogenic properties
The anticonvulsant properties of adenosine have been described in detail in the EILAT XII Progress Report. 3 In addition to its well-known anticonvulsant properties, adenosine has recently been found to have antiepileptogenic properties in animal models. 3 Local brain implants of adenosine-releasing silk rods placed into the brain ventricles of rats suppressed kindling epileptogenesis and prevented epilepsy progression in the rat systemic kainate model of temporal lobe epilepsy. It is notable that those effects were achieved by the transient delivery (10 days) of a sustained dose of 250 ng adenosine per brain ventricle per day. This transient dose of adenosine prevented disease progression long-term for at least 3 months. 5 We tested the antiepileptogenic efficacy of the ADK inhibitor 5-iodotubercidin (5-ITU) in the mouse intrahippocampal kainic acid model of temporal lobe epilepsy. As evidence for target engagement we found a dose-dependent
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• Many of the compounds presented show innovative mechanisms of action and promising findings in a variety of pharmacoresistant epilepsies, including previously neglected orphan indications inhibition of DNA methyltransferase activity in the hippocampus of 5-ITU-treated animals, which was comparable to that of standard DNA methyltransferase inhibitors. Three days after intrahippocampal kainic acid-induced status epilepticus (SE) in mice, 5-ITU was injected intraperitoneally (i.p.) at a dose of 1.6 mg/kg, b.i.d., for a restricted period of only 5 days. Six weeks and 9 weeks after SE, seizures were quantified by intrahippocampal electroencephalography (EEG). Although epileptic control animals treated with vehicle instead of 5-ITU developed a typical seizure rate of >20 seizures per hour, in the animals transiently exposed to an ADK inhibitor, both the seizure incidence as well as the total time spent in seizures were almost completely abolished. These data show that the transient systemic use of a small-molecule ADK inhibitor can prevent epileptogenesis and provides a rationale for developing small-molecule ADK inhibitors for antiepileptogenic therapies.
Other pharmacologic properties
As described previously, adenosine uniquely combines antiseizure, antiepileptogenic, neuroprotective, antipsychotic, and procognitive properties. 6 
Mechanism of action
The mechanisms responsible for the anticonvulsant properties of adenosine have been summarized in a previous report. 3 With respect to antiepileptogenesis, it is relevant to consider that adenosine is a metabolic product of the transmethylation pathway, which is also responsible for the methylation of -C-phosphate-G-(CpG) sites in the DNA. Whereas increased ADK (a pathologic hallmark of temporal lobe epilepsy) drives the flux of methyl groups through the transmethylation pathway and thereby increases DNA methylation, the augmentation of adenosine shifts the S-adenosyl-homocysteine hydrolase reaction, causing an increase in S-adenosyl-homocysteine production. S-adenosyl-homocysteine, in turn, inhibits DNA methyltransferases through product inhibition. 5 Through this mass action-based mechanism, a transient "therapeutic" dose of adenosine reduces DNA methylation status in the epileptic rodent brain, an action that could be responsible for the long-term attenuation of disease progression. These favorable mechanisms can be activated through direct focal adenosine delivery (e.g., via adenosine-releasing silk) and through systemic adenosine augmentation via small-molecule ADK inhibitors.
Toxicology
The safety of adenosine has been demonstrated in several preclinical and clinical safety studies, which are summarized in the EILAT XII Progress Report. 3 With respect to ADK inhibitors, a first generation of nucleoside and non-nucleoside ADK inhibitors was developed in the early 2000s for seizure suppression and for the treatment of chronic pain and inflammatory conditions. 9 These indications require chronic long-term dosing, which might not be feasible due to adverse effects on the liver and cardiovascular system. Peripheral adverse effects reported in preclinical studies in rodents with a variety of different systemically given ADK inhibitors 9 include reduction of body temperature, pulse rate, and respiration rate; and sedation and ataxia. Further development of one compound, GP-3966, was halted due to central nervous system (CNS) hemorrhage in rats and dogs. Both the beneficial and adverse effects of ADK inhibitors result from increased occupancy of system-wide adenosine receptors by elevated adenosine. This first generation of ADK inhibitors was developed with the aim of enhancing adenosine-receptor activation, a function that can be attributed to the cytoplasmic isoform ADK-S. 9 In contrast, the antiepileptogenic use of ADK inhibitors would require only a short-term treatment (days), thus avoiding adverse effects associated with chronic treatment regimens. In addition, the antiepileptogenic effects of adenosine could be more effectively exploited by targeting the nuclear isoform ADK-L. 5 Development of ADK inhibitors with a higher selectivity for ADK-L as opposed to ADK-S would be a strategy for boosting antiepileptogenic efficacy while reducing adverse effects associated with targeting of ADK-S.
Pharmacokinetic and metabolic profile
The pharmacokinetic and metabolic profiles of adenosine haves been summarized in a previous report. 3 A structurally novel class of ADK inhibitors is currently in development. Their pharmacokinetic and metabolic profiles still need to be determined.
Drug interactions
Adenosine's action on its receptors is antagonized by caffeine and theophylline.
Efficacy data
Efficacy data from investigations of adenosine for seizure suppression in animal models have been summarized previously. 3 Our most recent studies show that 5-ITU injected, i.p., at a dose of 1.6 mg/kg, b.i.d., for 5 days effectively prevents epileptogenesis in the mouse intrahippocampal kainic acid model.
Tolerability and adverse-effect profile
Tolerability data for adenosine administered intravenously (i.v.) to patients with supraventricular tachycardia have been summarized in the EILAT XII Progress Report. 3 With respect to ADK inhibitors, only one compound, GP-3269, has been investigated in phase I studies in humans, but data have not been disclosed. 9 It is expected that ADK inhibitors with a higher selectivity for ADK-L, coupled with the short-term use of these drugs, can avoid the adverse effects that limited the further development of the first generation of ADK inhibitors.
Introduction and rationale for development
SAGE-547 is a proprietary injectable aqueous formulation of allopregnanolone in betadex sulfobutyl ether cyclodextrin sodium (Captisol). Allopregnanolone is an endogenously occurring neuroactive steroid that modulates ligand-gated ion channels. It is a metabolite of progesterone in the CNS, as well as peripherally. Allopregnanolone acts as a highly potent positive allosteric modulator of synaptic and extrasynaptic c-aminobutyric acid (GABA) responses at the GABA A receptor, modulating both phasic and tonic GABAergic inhibition. Although synaptic GABA A receptors are down regulated during prolonged seizures, extrasynaptic GABA A receptors are retained. Unlike benzodiazepines, allopregnanolone modulates both synaptic and extrasynaptic GABA A receptors, and through these actions it elicits potent anxiolytic, sedative, and anticonvulsant effects in preclinical models in vitro and in vivo.
SAGE-547 is being developed for the treatment of superrefractory status epilepticus (SRSE), a severe form of SE that continues for >24 h despite multiple therapeutic interventions and/or failure to be weaned from third-line agents. There are as yet no treatments for SRSE approved by the U.S. Food and Drug Administration (FDA).
Pharmacology

Anticonvulsant profile
Allopregnanolone has been shown to have efficacy in the treatment of seizures and SE in many preclinical animal models, including the pentylenetetrazole (PTZ), 6 Hz, bicuculline, picrotoxin, pilocarpine, and kainate seizure models. 12, 13 Details of its activity profile in these models are provided in the EILAT XII Progress Report. 3 
Mechanism of action
As detailed in the EILAT XII Progress Report, 3 the anticonvulsant activity of allopregnanolone is mediated by allosteric potentiation of GABA A -receptor function. 14 Allopregnanolone also modulates the binding of a variety of other ligands to the GABA A receptor. 3 
Pharmacokinetic and metabolic profile
The pharmacokinetics of intravenously administered allopregnanolone have been investigated in two studies, 15, 16 which are summarized in detail in the EILAT XII Progress Report. 3 
Efficacy data
An open-label phase I/II clinical trial (547-SSE-201) was conducted to study the safety, tolerability, and efficacy of SAGE-547 in patients with SRSE. The study design has been described in more detail previously. 3 Included were patients who had been in SE for at least 24 h despite treatment with first-and second-line SE treatments and who had either failed to have SE controlled after 24 h using a third-line general anesthetic agent or had failed at least one third-line anesthetic wean attempt. After an initial loading dose (286.6 lg/kg for 1 h), study patients were treated with 4 days of SAGE-547 at either a standard (86 lg/kg/h) or high (156 lg/kg/h) maintenance dose, and after 4 days of maintenance dosing, patients were subsequently tapered from SAGE-547. Follow-up was conducted after 2 days and then after an extended 3-week period. The efficacy of SAGE-547 in SRSE patients (response to treatment) was assessed based on the need to place the patient back under general anesthesia for seizure control during administration of SAGE-547 prior to taper, as well as by the duration of response and changes in behavior as measured by rating scales of agitation, depth of coma, and survival.
In this phase I/II study, SAGE-547 demonstrated robust activity, with 77% of 22 evaluable patients meeting the key efficacy end point of being successfully weaned off their anesthetic third-line agents while SAGE-547 was being administered. In addition, 73% of the total evaluable patients were successfully weaned off SAGE-547 without recurrence of SRSE in the 24-h period following treatment. The response rate among patients receiving a standard SAGE-547 dose was 81% (n = 13/16 patients), whereas the response rate among patients receiving a high SAGE-547 dose was 67% (n = 4/6 patients). In addition, SAGE-547 produced significant and dose-dependent suppression of seizure activity as assessed by EEG activity. During the follow-up period, one patient had a recurrence of SE within 2 weeks post-SAGE-547 administration, whereas three patients had recurrences during study weeks 2-4.
In the evaluable population of 22 patients, there was no evidence of a relationship between SAGE-547 efficacy and patient characteristics (gender, age, or ethnicity). These patients also showed no evidence of a relationship between efficacy and the number of underlying AEDs or anesthetic third-line agents (range of AEDs, 2-4; range of third-line agents, 1-2). However, a potential relationship between efficacy and the number of concomitant third-line agents was observed, as only 40% of subjects with three concomitant third-line agents were successfully weaned from their thirdline agents prior to the end of SAGE-547 maintenance.
Tolerability and side effect profile
In the phase I/II SAGE-547 trial in patients with SRSE, safety and tolerability were assessed via monitoring of treatment-emergent adverse events (AEs), EEG, physical and neurologic examinations, vital signs, clinical laboratory measures, electrocardiography (ECG), and concomitant medication use. SAGE-547 demonstrated favorable tolerability and a benefit-risk profile supporting further development for this acutely ill patient population. The most common AE in the study population was pyrexia (20%), followed by anemia, increase in blood urea, diarrhea, hypotension and peripheral edema (all 16% each). Overall, 64% of patients experienced at least one serious AE, although none were drug-related as determined by the Safety Review Committee. Serious AEs occurring in ≥8% of patients were respiratory failure (12%), convulsion (8%), pulmonary embolism (8%), acute renal failure (8%), and sepsis (8%). Independent of treatment response, six patient deaths occurred within the study period, all driven by underlying medical conditions.
Planned studies
SAGE-547 is currently being investigated in a randomized, double-blind, placebo-controlled phase III trial (SAGE-547 Treatment as Adjunctive Therapy Utilized in Status Epilepticus [STATUS] Trial; 547-SSE-301) (Fig. 1) . The goal of this study is to investigate the safety and efficacy of SAGE-547 administration in patients with SRSE. Patients enrolled in this trial are randomized 1:1 (SAGE-547 to placebo) and treated for 1-6 days with SAGE-547. Patients for whom SE fails to be resolved are eligible for open-label treatment with high-dose SAGE-547. Patient follow-up is conducted after 21 days. The primary end point of the study is continued resolution of SE for 24 h following wean of all third-line agents and SAGE-547/placebo.
Introduction and rationale for development
Brivaracetam is a selective, high-affinity ligand for synaptic vesicle protein 2A (SV2A) that has been approved recently by the European Medicines Agency (EMA), Health Canada Health Products and Food Branch (HPFB), and the FDA as adjunctive treatment for focal (partial-onset) seizures in adults (≥16 years) with epilepsy. Levetiracetam, the first agent in this drug class, has only modest affinity for SV2A and has other non-SV2A mechanisms related to inhibition of high voltage-activated calcium channels and inhibition of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-gated currents. 17 This triggered a major drug discovery program to identify selective, highaffinity SV2A ligands possessing antiepileptic properties superior to levetiracetam in animal models of seizures and epilepsy. These efforts led to the discovery of brivaracetam. 17 
Pharmacology
Anticonvulsant profile
Brivaracetam provides more potent and complete seizure suppression than levetiracetam in a wide range of animal models of focal, primary generalized, and drug-resistant seizures at doses devoid of psychomimetic effects consisting of circling, head weaving, and hyperlocomotion, 18 and with no impact on motor or cognitive function. 17, 19 More recently, brivaracetam also displayed high potency in a mouse 6 Hz kindling model, further supporting its potential efficacy in treatment-resistant epilepsy. 20 Brivaracetam has higher lipophilicity than levetiracetam, resulting in greater blood-brain barrier permeability and faster brain penetration, thereby leading to a more rapid onset of action in audiogenic seizure-susceptible mice. 21 Supportive positron emission tomography (PET) studies in rhesus monkeys reported estimated half-times for brain occupancy of SV2A of approximately 3 and 23 min for brivaracetam and levetiracetam, respectively, after intravenous administration. 21 
Mechanism of action
Brivaracetam's binding affinity for SV2A is selective and approximately 15-to 30-fold higher than that of levetiracetam. 22 Recent experiments with an SV2A allosteric modulator demonstrated that brivaracetam's interaction with SV2A differs from that of levetiracetam, likely inducing or stabilizing different SV2A protein conformations. 23 This probably explains findings from electrophysiologic studies in rat hippocampal slices showing a superior ability of brivaracetam to inhibit synaptic transmission and vesicle release, 24 which correlates with its distinct pharmacodynamic properties. 17 Brivaracetam also differs from levetiracetam by not inhibiting the AMPA receptor and high voltage-activated calcium channels. 17 It was previously thought that inhibition of voltage-activated sodium channels might contribute to an additional mechanism of action for brivaracetam. However, further experiments were unable to consistently reproduce these findings and demonstrated no effect against sustained repetitive neuron firing, 25, 26 in line with the protection against maximal electroshock seizures (MES) occurring only at high, supratherapeutic doses of brivaracetam. 17 These findings suggest that the antiepileptic activity of brivaracetam derives from its selective interaction with SV2A.
Toxicology
Brivaracetam showed low acute toxicity in mice, rats, and dogs, as summarized previously. 27 Brivaracetam demonstrated no teratogenic potential in rats or rabbits. 28 
Pharmacokinetic and metabolic profile
The pharmacokinetics of brivaracetam have been described in detail in the EILAT XII Progress Report. 3 In summary, in healthy subjects, the drug is rapidly and completely absorbed from the gastrointestinal tract, is <20% bound to plasma proteins, and is eliminated with a half-life of approximately 9 h, partly by hydrolysis to the inactive carboxylic acid metabolite (the predominant metabolic pathway) and partly by cytochrome P450 (CYP)2C19-dependent hydroxylation. The enzyme responsible for the main biotransformation pathway was recently identified as amidase EC 3.5.1.4. 
Exposure-response modeling
A population pharmacokinetic/pharmacodynamic model was developed to describe the relationship between brivaracetam exposure and daily focal seizure reduction. 30 The plasma concentration at 50% of the maximum seizure frequency reduction (EC 50 ) in the mixture-model responder population was estimated to be 0.57 mg/L in the final covariate model. This concentration is slightly above the median exposure obtained after brivaracetam doses of 50 mg/day. Further seizure frequency reduction was obtained by increasing the dose to 100 mg/day, and reached a plateau at 200 mg/day. 30 
Drug interactions
Coadministration with carbamazepine, phenytoin, and phenobarbital has been found to decrease brivaracetam exposure by 26%, 21%, and 19%, respectively, without significant effects on response. 30 However, brivaracetam exposure was decreased by 45% when the drug was coadministered with the potent inducer enzyme rifampicin, which may require dose adjustment. 29 Brivaracetam does not significantly inhibit drug transporters or CYP enzymes in vitro. 31 In phase II and III clinical trials in adults with epilepsy, adjunctive brivaracetam did not affect plasma concentrations of concomitantly administered carbamazepine, clobazam, clonazepam, lacosamide, levetiracetam, lamotrigine, oxcarbazepine's monohydroxyderivative, phenobarbital, phenytoin, pregabalin, primidone, topiramate, valproic acid, and zonisamide. 32 However, the plasma concentration of carbamazepine-10,11-epoxide was elevated at the highest brivaracetam dose of 200 mg/day, 32 reaching a mean value of 3.25 lg/ ml, which corresponds to a 1.98-fold increase (90% confidence interval [CI] 1.89-2.08) from baseline. By comparison, in the placebo group, the concentration of carbamazepine-10,11-epoxide was 1.76 lg/ml, corresponding to a 0.99-fold (CI 0.97-1.02) change from baseline (UCB Pharma, data on file). Similarly, in a pharmacokinetic interaction study in adults with epilepsy, brivaracetam 100-400 mg/day did not modify exposure to carbamazepine but caused a dose-dependent and reversible increase in the plasma concentrations of carbamazepine-10,11-epoxide, both with and without concomitant valproic acid. 33 The elevated carbamazepine-10,11-epoxide concentration, however, did not reach the threshold of ≥8 lg/ml that has been associated with neurotoxicity. 34 Further analysis of safety data from three fixed-dose, phase III studies, in which 41% of brivaracetam-treated patients were taking concomitant carbamazepine, does not support an association between carbamazepine-10,11-epoxide levels and symptoms of toxicity. 35 Consequently, no dose adjustment is required when brivaracetam is added to most commonly used AEDs.
Efficacy data
Phase III studies
Three fixed-dose, multicenter, randomized, double-blind, placebo-controlled, phase III trials have been completed (N01252/NCT00490035, N01253/NCT00464269, and N01358/NCT01261325). All trials were conducted in adults with uncontrolled focal seizures despite treatment with 1-2 AEDs. Patients received adjunctive brivaracetam or placebo for 12 weeks, with brivaracetam initiated at the target dose, without titration. Data from studies N01252 (brivaracetam 20, 50, or 100 mg/day) and N01253 (brivaracetam 5, 20, or 50 mg/day) have been summarized previously. 3 Study N01358 is one of the largest phase III studies in epilepsy to date, with 768 randomized patients. 36 In study N01358, patients received adjunctive brivaracetam (100 or 200 mg/day in two divided doses) for 12 weeks without titration, or placebo. Patients taking concomitant levetiracetam were excluded. Almost half of the patients in the intent-to-treat (ITT) population (359/760, 47.2%) had previously failed ≥5 AEDs, including levetiracetam in some patients. The primary efficacy end points were percent reduction over placebo in 28-day baseline-adjusted focal seizure frequency and ≥50% responder rate. Overall, 696 (90.6%) of 768 patients completed the study. Both primary efficacy end points were achieved for both brivaracetam doses (Fig. 2) . Percent reduction over placebo in 28-day baseline-adjusted focal seizure frequency was 22.8% (p < 0.001) and 23.2% (p < 0.001) for brivaracetam 100 and 200 mg/day, respectively. Furthermore, ≥50% responder rates were significantly higher for both brivaracetam doses compared with placebo (100 mg/day: 38.9%, p < 0.001; 200 mg/day: 37.8%, p < 0.001; placebo: 21.6%). Seizure freedom rates (all seizures) were 5.2% (p = 0.003) for brivaracetam 100 mg/day, 4.0% (p = 0.019) for brivaracetam 200 mg/day, and 0.8% for placebo.
In a pooled analysis of the three fixed-dose, phase III studies, excluding patients taking concomitant levetiracetam, ≥50% responder rates were higher for brivaracetam Figure 2 . Primary efficacy outcomes for study N01358 (ITT population). Percent reduction over placebo in 28-day baseline-adjusted focal seizure frequency during the treatment period (A); ≥50% responder rate for focal seizure frequency from baseline to the end of treatment period (B). Error bars represent 95% confidence interval. BRV, brivaracetam; ITT, intention-to-treat; PBO, placebo. Figure reproduced with permission from Blackwell Publishing Inc., from Klein et al. 36 ; permission conveyed through Copyright Clearance Center, Inc. Epilepsia ILAE 50, 100, and 200 mg/day (34.2%, 39.5%, and 37.8%, respectively) compared with 20.3% for placebo. 37 In two of the early phase III studies, approximately 20% of patients received levetiracetam as a concomitant AED. In this limited number of patients receiving concomitant levetiracetam therapy, no added benefit was reported for brivaracetam versus placebo, which may reflect competition at the SV2A binding site. [38] [39] [40] A post hoc subgroup analysis of study N01358 included 413 previously levetiracetam-exposed patients and 347 levetiracetam-naive patients. Focal seizure reduction was observed in brivaracetam-treated patients in both groups, with a numerically greater effect in levetiracetam-naive patients. 36 Pooled data from the three fixed-dose, phase III studies were used in a further post hoc subgroup analysis according to prior exposure to four commonly used AEDs: levetiracetam, carbamazepine, lamotrigine, and topiramate. 41 Similar to the N01358 analysis, ≥50% responder rates were consistently higher for levetiracetam-naive patients (37.2%, 48.3%, and 45.2% for brivaracetam 50, 100, and 200 mg vs. 22.5% for placebo) than for patients previously exposed to levetiracetam (27.1%, 29.7%, and 31.3%, respectively, vs. 17.8% for placebo). Higher brivaracetam efficacy was also seen in patients who were naive to carbamazepine, lamotrigine, or topiramate compared with their previously exposed counterparts. For each AED evaluated, more patients in the previously exposed subgroup had failed ≥5 prior AEDs than in the corresponding AED-naive subgroup, suggesting that these patients had more refractory epilepsy.
Secondarily generalized tonic-clonic seizures are associated with injury, falls, and sudden unexpected death in epilepsy (SUDEP). In a post hoc exploratory analysis of pooled fixed-dose, phase III data from patients with secondarily generalized tonic-clonic seizures at baseline, ≥50% responder rates for secondarily generalized tonic-clonic seizures were 61.3%, 55.0%, and 64.0% for brivaracetam 50, 100, and 200 mg/day, respectively, compared with 33.0% for placebo (nominal p-values p = 0.003, p < 0.001, and p < 0.001, respectively). 42 Freedom from secondarily generalized tonic-clonic seizures was achieved by 22.6%, 31.0%, and 36.0% of patients treated with brivaracetam 50, 100, and 200 mg/day, respectively, compared with 14.8% for placebo. Therefore, reduction in secondarily generalized tonic-clonic seizures frequency has been observed in patients with this seizure type at baseline treated with brivaracetam.
In a post hoc analysis of pooled fixed-dose, phase III data, sustained ≥50% responder status was used as an indicator of onset of action. 43 Patients were classified as sustained ≥50% responders at a particular day if they completed the treatment period and were a ≥50% responder on that day and for every successive day until the end of the treatment period. Sustained ≥50% responder status was achieved on the first day of treatment for ≥15.5% of patients taking brivaracetam 50, 100, or 200 mg/day (pooled treated population) versus 6.7% for placebo (p < 0.001), suggesting that brivaracetam has an early, sustained onset of action in a subset of responders.
Brivaracetam 50-200 mg/day was effective in a small subgroup of elderly patients (≥65 years, n = 32) included in the phase III studies. 44 Long-term follow-up studies Data were pooled from 1,904 adults with uncontrolled focal seizures who received adjunctive brivaracetam 5-200 mg/day for up to 8 years in three open-label, long-term studies (N01125/NCT00175916; N01199/NCT00150800; and N01379/NCT01339559) continuing from the phase IIb/ III studies. 45 Overall 1,500, 1,188, 847, and 553 patients received brivaracetam for 6, 12, 24, and 60 months, respectively. The overall ≥50% responder rate was 48.9%, with ≥50% responder rates of 49.3%, 56.4%, 63.2%, and 66.4% in the 6-, 12-, 24-, and 60-month cohorts, respectively.
Tolerability and adverse effect profile
Adjunctive brivaracetam displayed a favorable safety and tolerability profile in the three fixed-dose, phase III studies and in an additional flexible-dose, phase III safety study (N01254/NCT00504881). 3, 36 In study N01358, at least one treatment-emergent AE was reported by 67.6% of brivaracetam-treated patients and 59.4% of patients on placebo. 36 Discontinuation rates due to AEs were low (8.3% and 6.8% for brivaracetam 100 and 200 mg/day, respectively, vs. 3.8% for placebo). AEs reported in ≥5% of patients taking brivaracetam were somnolence (brivaracetam 18.1%, placebo 7.7%), dizziness (12.3%, 5.0%), fatigue (9.5%, 3.8%), and headache (7.4%, 8.4%). The incidence of serious AEs was low and similar for brivaracetam and placebo (3.2% and 3.4%, respectively).
In a pooled analysis of the three fixed-dose, phase III studies, including patients taking concomitant levetiracetam, at least one AE was reported by 68.0% of patients receiving brivaracetam 50-200 mg/day and 62.1% on placebo. 46 The most commonly reported AEs were somnolence (brivaracetam 15.2%, placebo 8.5%), dizziness (11.2%, 7.2%), headache (9.6%, 10.2%), and fatigue (8.7%, 3.7%). Most AEs were of mild or moderate severity. Serious AEs were infrequent (brivaracetam 3.0%, placebo 2.8%). Discontinuation rates due to AEs were 6.7% for brivaracetamtreated patients and 3.9% for placebo. 46 A pooled analysis of two phase IIb studies, six phase III studies, and four ongoing long-term follow-up studies included data from 2,388 adults who received adjunctive brivaracetam 5-200 mg/day, with a total exposure of 5,558 patient-years. 47 Overall, 84.8% of patients reported AEs and 14.1% discontinued treatment due to AEs. The most frequently reported AEs were headache (20.9%), dizziness (17.3%), somnolence (15.2%), nasopharyngitis (12.7%), fatigue (11.5%), and convulsion (10.5%). Serious AEs were reported by 18.1% of patients, most commonly convulsion (2.5%), SE (0.8%), and pneumonia, epilepsy, grand mal convulsion, suicidal ideation, and suicidal attempt (0.5% each).
Pooled data were analyzed from two phase IIb studies, four phase III studies, and four ongoing long-term followup studies to determine retention rates for adjunctive brivaracetam 50-200 mg/day for the treatment of focal seizures. 48 The start of exposure was defined as the day of the first brivaracetam dose. Retention rates were based only on patients who discontinued due to lack of efficacy or AEs. Kaplan-Meier estimated retention rates were 95.9% after 12 weeks and 79.8% after 52 weeks.
Planned studies
Several long-term, open-label, follow-up trials of adjunctive brivaracetam in patients with focal epilepsy are in progress. In addition, an ongoing PET study in healthy subjects is estimating the speed of entry into the brain for brivaracetam and levetiracetam. A noninterventional study is collecting real-world data on brivaracetam efficacy as adjunctive therapy in patients with focal seizures. Studies in pediatric patients are planned, including a randomized, controlled, double-blind efficacy and safety study of adjunctive brivaracetam for focal seizures in children aged 1 month to <4 years.
Introduction and rationale for development
Bumetanide, or 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid, is a potent, fast-acting loop diuretic, 49 which has been used clinically for many decades. Its diuretic effects result from blocking the renal Na-K-2Cl-cotransporter (NKCC2) in the apical membrane of the epithelial cells that form the thick ascending limb of the Henle's loop in the kidney. 50 In addition to NKCC2, bumetanide blocks NKCC1, which is ubiquitously expressed in many tissues, including the brain, and plays a major role in the regulation of intracellular chloride ion concentration. 51 In brain neurons, NKCC1 is thought to be involved in deranged cellular chloride homeostasis in several brain diseases, such as neonatal seizures, epilepsy, autism, and ischemic and traumatic brain injury (TBI). 51 This has sparked considerable interest in using bumetanide for treating such disorders, which are often refractory to standard therapies.
Use of bumetanide for preventing or treating epilepsy, however, is hampered by its poor brain penetration, which is ascribed to its high plasma protein binding (~97-98%) and extensive ionization (>99%) at physiologic pH, 52 which limits its ability to enter the brain by passive diffusion. Brain concentration of bumetanide is further reduced by organic anion transporters actively facilitating brain efflux of the compound upon entrance. Bumetanide concentrations found in the brain are only approximately 1-2% of concentrations found in plasma, meaning that tolerable systemic doses of bumetanide yield brain concentrations below those required to affect neuronal NKCC1. This is a likely explanation for the disappointing negative results of the first clinical phase I/II trial with bumetanide in newborn infants with seizures, in which bumetanide was not effective and increased the risk of hearing loss. 53 Over the past~10 years, we explored several strategies to improve the use of bumetanide or its derivatives for the treatment of brain disorders such as epilepsy. These strategies included the following: (1) development of lipophilic, noncharged bumetanide prodrugs that enter the brain before cleavage to bumetanide; (2) inhibition of the brain efflux of bumetanide with probenecid; (3) coadministration of piperonyl butoxide, a compound that inhibits the rapid metabolism of bumetanide; and (4) testing of various bumetanide derivatives that were synthesized in the 1960s and 1970s at Leo Pharma (Copenhagen, Denmark) as part of the screening for diuretic compounds that finally resulted in the discovery of bumetanide (Fig. 3) . 54 The aim of the fourth strategy was to find NKCC1-selective drugs with low diuretic and ototoxic potencies. The first three strategies increased bumetanide levels in rodent brains and the prodrug strategy, in addition, resulted in reduced diuretic activity compared with that of bumetanide. [55] [56] [57] Because the fourth strategy did not identify NKCC1-selective drugs, the interdisciplinary group performing these studies started to synthesize various novel bumetanide derivatives, which are currently being evaluated. Principal investigators of the interdisciplinary group include Thomas Erker (Vienna, Austria), Kai Kaila (Helsinki, Finland), Nanna MacAulay (Copenhagen, Denmark), Kevin Staley (Boston, Massachusetts, United States), Peter W. Feit (Travem€ unde, Germany), and Wolfgang L€ oscher (Hannover, Germany).
Pharmacology
Bumetanide
The pharmacologic effects of bumetanide in models of seizures and epilepsy have been reviewed in detail 60 and T€ ollner et al. 56 Epilepsia ILAE recently. 52, 58 Bumetanide is ineffective in standard seizure models such as the MES and PTZ seizure tests up to doses of 75 mg/kg. For comparison, the maximal effective diuretic dose in infants is~0.04 mg/kg, and typical doses in adults range from 1 to 2 mg (i.e.,~0.015-0.03 mg/kg). Much higher doses of bumetanide have been evaluated in various seizure models, and most reports found no effect. 52, 58 Likely explanations include the low expression of NKCC1 in nonepileptic rodents and the poor brain penetration of bumetanide. However, bumetanide was reported to enhance the antiseizure effect of phenobarbital in models of neonatal seizures. Furthermore, bumetanide has been found to moderately enhance the effect of phenobarbital in adult kindled rats. 56 
Bumetanide prodrugs
To overcome the problem of poor brain penetration, we designed lipophilic and uncharged bumetanide prodrugs that could penetrate the blood-brain barrier more easily than the parent drug and be converted to bumetanide in the brain. 56 The feasibility of this strategy was evaluated in mice and rats. Analysis of bumetanide levels in plasma and brain showed that administration of two ester prodrugs of bumetanide, the pivaloyloxymethyl (BUM1) and N,N-dimethylaminoethylester (BUM5; Fig. 3 ), resulted in significantly higher brain levels of bumetanide than administration of the parent drug. BUM5, but not BUM1, was less diuretic than bumetanide, and therefore BUM5 was further evaluated in chronic models of epilepsy in mice and rats. In the pilocarpine model in mice, BUM5, but not bumetanide, counteracted the alteration in seizure threshold during the latent period. In the kindling model in rats, BUM5 was more efficacious than bumetanide in potentiating the anticonvulsant effect of phenobarbital. We also showed that BUM5, but not bumetanide, markedly potentiates the effect of phenobarbital on the PTZ seizure threshold in epileptic mice. 59 These data demonstrate that the goal to design bumetanide prodrugs that specifically target the brain is feasible, and that such drugs may resolve some of the problems associated with using bumetanide for treatment of CNS disorders. However, the potential of bumetanide to induce ototoxicity is likely not reduced by this approach.
Other bumetanide derivatives
The discovery of bumetanide resulted from systematic structure-activity studies of a large series of diuretically active 3-amino-5-sulfamoylbenzoic acid derivatives, and was followed by the investigation of several series of compounds related both in chemical structure and diuretic profile. 54 In other words, the synthesis of these compounds was performed when the mechanistic background for sulfamoyl diuretics was by no means elucidated. 54 More than 5,000 3-amino-5-sulfamoylbenzoic acid derivatives were synthesized in the 1960s and 1970s at Leo Pharma by Peter Feit and his group during screening for compounds with high diuretic efficacy. Our hypothesis when reevaluating these compounds was that modifications of bumetanide that decrease its diuretic potency (and affinity for NKCC2) may eventually increase the selectivity for NKCC1.
We performed a structure-activity study in which the affinity of various bumetanide derivatives for NKCC2 was compared with their diuretic potency. 60 A good correlation between the diuretic potency of these compounds and their inhibition of NKCC2 was found (r 2 = 0.817; p < 0.01). Replacement of the carboxylic group of bumetanide by a nonionic residue, for example, an aniline-methyl group, resulted in a loss of inhibition of NKCC2, indicating that an acidic group is a requirement for transporter inhibition. Exchange of the phenoxy group of bumetanide by a 4-chloroanilino group or the sulfamoyl group by a methylsulfonyl group resulted in compounds with higher potency as inhibitors of NKCC2 than bumetanide. In a subsequent as yet unpublished study, we compared the inhibitory potencies of these bumetanide derivatives for NKCC1. Side-chain substitutions in the bumetanide molecule variably affected the potency to inhibit NKCC1. This allowed a definition of the minimal structural requirements necessary for ligand interaction.
Toxicology
Excessive doses of bumetanide can lead to profound water loss, electrolyte depletion (especially hypokalemia), dehydration, reduction in blood volume, and circulatory collapse with the possibility of vascular thrombosis and embolism. In cats, dogs, and guinea pigs, bumetanide has been shown to produce ototoxicity, which has been also reported after high doses of bumetanide in humans, including infants. Furthermore, bumetanide may potentiate the ototoxicity of aminoglycosides such as gentamycin, resulting in temporary, or in some cases, permanent loss of hearing. The ototoxicity is thought to be mediated by inhibition of NKCC1 in the inner ear, thus blocking the generation of the endocochlear potential, which is necessary for cochlear amplification. However, more recent studies have shown that NKCC2, which is typically recognized as a kidney-specific ion transporter, is also expressed in several other tissues, including the rat and human inner ear, most likely regulating in concert with NKCC1 the homeostasis of the endolymph, so that NKCC2 dysfunction may, as well, be involved in hearing loss in response to bumetanide.
During the characterization of the various bumetanide derivatives described above, we mainly examined diuretic potency and the resulting hypokalemia. Part of our strategy was to search for derivatives with higher brain penetration but less diuretic potency compared to bumetanide. In the future, we plan to characterize also the risk of ototoxicity by developing compounds that do not interfere with the NKCC1 splice variants expressed in the inner ear (see below).
Pharmacokinetic and metabolic profile
Bumetanide is rapidly and almost completely absorbed after oral administration, and it undergoes extensive metabolism. 49 In adults, the half-life of the drug is on the order of 0.8-1.5 h. Longer half-life values (approximately 6 h, with a range of up to 15 h) have been reported in infants. The pharmacokinetics of the bumetanide derivatives described here are known for only mice and rats. 56 
Efficacy data
There is little clinical evidence for bumetanide's antiseizure efficacy. 3 A recently published phase I/II openlabel exploratory dose-finding and pharmacokinetic study aimed at estimating the optimal dose of bumetanide for the treatment of neonates with seizures which did not respond to an initial loading dose of phenobarbital. 53 This trial, which used intravenous bumetanide doses ranging from 0.05 to 0.3 mg/kg, was terminated early due to ototoxicity and lack of efficacy. 53 Another clinical dose-finding study of bumetanide as an antiseizure treatment in neonatal seizures is currently ongoing in the United States (http://www.clinicaltrials.gov/ct2/show/NCT00830531). This is a randomized, double-blind dose-escalation pilot study comparing standard phenobarbital therapy with standard phenobarbital therapy combined with 0.1, 0.2, or 0.3 mg/kg bumetanide.
None of the bumetanide derivatives characterized by the interdisciplinary team described above has been tested in humans.
Tolerability and adverse effect profile
AEs of bumetanide related to its diuretic effect include fluid loss, hypotension, electrolyte disturbances, and hyperglycemia. 49 As discussed earlier, similar to other loop diuretics, bumetanide can cause ototoxicity.
Planned studies
For both NKCC1 and NKCC2, several splice variants have been described. 50 The three full-length NKCC2 splice variants (NKCC2A, NKCC2B, and NKCC2F) differ in their location along the thick ascending limb of the Henle's loop and their transport characteristics, but exhibit similar sensitivity to inhibition by bumetanide. Splice variants of NKCC1 are less well characterized: a full-length NKCC1 transcript (NKCC1A) and a shorter splice variant (NKCC1B) have been described. Both form functional cotransporters and vary in their tissue distribution in humans. 61 Both NKCC1A and NKCC1B are expressed in the human brain, but expression of NKCC1B is several-fold larger than that of NKCC1A, whereas the opposite is true in most other tissues. 61 Recently, NKCC1B has been suggested to play a critical role in the pathophysiology of schizophrenia, especially during fetal age or early brain development. 62 Thus, provided that the two splice variants of NKCC1 differ in their pharmacology, which is presently not known, a compound that selectively inhibits NKCC1B would be an interesting lead structure for targeting the human brain in diseases involving altered functionality of the cotransporter. We plan to study the effect of various bumetanide derivatives on the different splice variants of NKCC1.
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Introduction and rationale for development
Cannabidiol has been used to treat epilepsy for decades in various formulations, but well-controlled studies are lacking. Various reports have shown effects and others no effect at all. 63 A recent Cochrane review on cannabinoids for treatment of epilepsy concluded that there was not enough data to draw conclusions and that more research was necessary to determine if they may be efficacious in the treatment of epilepsy. 64 Cannabidiol is a nonpsychoactive component of the Cannabis sativa plant that has shown antiepileptic effects in animals and in recent human data. GW Pharmaceuticals has initiated a full development program for a pharmaceutical liquid formulation of purified cannabidiol (Epidiolex). If approved, it would be a first-in-class AED. Cannabidiol is presently in phase III development for Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex (TSC), and infantile spasms, and it has received orphan drug designation from the FDA for each of these potential indications.
Pharmacology
Anticonvulsant profile
Cannabidiol exhibits anticonvulsant activity in both in vitro and in vivo models of seizures. 63 When examined in hippocampal slice models of epileptiform activity indicative of SE (Mg +2 free and 4-aminopyridine), cannabidiol demonstrated efficacy at concentrations ≥10 nM. 65 In these models, cannabidiol reduced local field potentials, burst duration, frequency, and amplitude. A recent meta-analysis revealed that cannabidiol, examined in 21 preclinical conditions, models, or experimental paradigms relating to seizures, is anticonvulsant in 17 (81%) and inconclusive in the remaining 4 (19%). 66 No studies reported proconvulsant activity. Cannabidiol has shown anticonvulsant effects in a number of acute seizure models. 67 In a pharmacoresistant model of temporal lobe seizure (pilocarpine), cannabidiol (≥1 mg/kg, i.p.) significantly reduced the number of animals exhibiting seizures and the number of seizures. In the intracerebroventricular (i.c.v.) penicillin model of focal seizures, cannabidiol significantly reduced the incidence of seizure-related mortality at doses ≥10 mg/kg, i.p. 68 Cannabidiol also demonstrated efficacy in a model of generalized seizures (i.p. PTZ).
Cannabidiol (100 mg/kg, i.p.) coadministered with ethosuximide or valproic acid in an acute PTZ model of seizures, retained its anticonvulsant effects and was well tolerated. In addition, cannabidiol demonstrated additive/synergistic interactions with valproic acid in this seizure model, consisting of reducing seizure severity, increasing latency to seizure onset, and reducing the occurrence of the higher seizure states.
Other pharmacologic properties
In comparison to valproic acid, ethosuximide, and phenobarbital, cannabidiol did not produce any motor deficits or neurotoxicity in tolerability assays (GW Pharmaceuticals data on file). These data suggest that cannabidiol may be well tolerated in the clinical setting.
Mechanism of action
Cannabidiol possesses a rich poly-pharmacology, exhibiting affinity and functional agonism or antagonism at multiple 7-transmembrane receptors, ion channels, and neurotransmitter transporters. 66 The extent to which each of these mechanisms is responsible for the antiseizure properties of cannabidiol is undergoing investigation. A proportion of the targets engaged by cannabidiol have been shortlisted for such investigations based on their physiologic relevance to maintenance of normal neuronal function, for example, intracellular calcium mobilization, membrane potential, and neurotransmitter release (and uptake). Because cannabidiol neither binds to nor activates the cannabinoid CB 1 and CB 2 receptors at clinically relevant concentrations, the role of these receptors in cannabidiol's antiseizure activity has been excluded. 66 Similarly, cannabidiol does not modulate the function of sodium channels. 69 Ongoing studies are focused on the prime candidate targets, namely adenosine reuptake and G protein-coupled receptor 55 (GPR55) antagonism. Indeed, data generated by Bazelot and presented at the 2016 Annual Meeting of the American Academy of Neurology in Vancouver, Canada, support the hypothesis that cannabidiol is a GPR55 antagonist. Here, cannabidiol (10 lM) was able to reverse L-alysophosphatidylinositol-induced increases in miniature excitatory postsynaptic currents (mEPSCs) frequency in CA1 pyramidal cells of epileptic tissue.
Toxicology
In the development of Epidiolex, cannabidiol underwent an extensive preclinical program consisting of toxicology (genetic, reproductive, repeat-dose ,and juvenile toxicity studies), safety pharmacology (rat CNS, rat respiratory, dog telemetry studies plus hERG channel and rabbit Purkinje fiber in vitro cardiac assays), and absorption-distributionmetabolism-excretion programs. In addition, an abuse potential program is ongoing. Reports of these studies are in the process of being completed and published.
Pharmacokinetic and metabolic profile
Cannabidiol is known to be highly lipophilic, with a terminal half-life in humans estimated at 18-32 h. 70 The major CYP isoform involved in cannabidiol metabolism is CYP2C19 to form 7-OH-cannabidiol, which is metabolized further by CYP3A4 to 7-COOH-cannabidiol. There are other minor routes involving hydroxylations on other parts of the molecule mediated by multiple CYP isoforms, and the resulting metabolites are excreted in the feces and to a much lesser extent in the urine.
A formal single-and multiple-dose human pharmacokinetic study in healthy adult volunteers has been completed, but the final study report has not been published.
Drug interactions
In a recent small case series report on the effect of cannabidiol on clobazam and N-desmethylclobazam levels in pediatric patients with refractory epilepsy who were taking multiple concomitant AEDs, Geffrey et al. 71 reported after 4 weeks of cannabidiol treatment increases in plasma clobazam levels of 60 AE 80% (mean AE standard deviation [SD]) with 95% confidence level (CI) of À2% to 91% and N-desmethylclobazam levels of 500 AE 300% (mean AE SD) with 95% CI of +90 to 610%. The increase in plasma N-desmethylclobazam reported in this study are consistent with the known inhibitory effects of cannabidiol on CYP2C19, the major isoform involved in N-desmethylclobazam metabolism.
Additional studies on food effects and drug-drug interaction studies in healthy volunteers and patients with refractory epilepsy are ongoing.
Efficacy data
The efficacy of cannabidiol was examined initially in several trials with methodologic limitations that did not enable adequate assessment, as concluded by the Cochrane review. 64 An expanded access program in patients with treatment-resistant epilepsy who are not candidates for GW Pharmaceuticals-sponsored clinical trials has been conducted since early 2014. The first peerreviewed publication of this open-label program included 137 patients with at least 12 weeks of follow-up for analysis of seizure reductions. 72 Patients averaged 10.5 years of age and were taking an average of three AEDs. The mean cannabidiol dose was 22.7 mg/kg at week 12 for this group. The primary end point was the median percentage reduction in mean monthly motor (convulsive) seizures, which was 36.5% with 4% free of motor seizures over the entire 12-week period. A report of a larger cohort from the same extended access program was presented in a poster format at the 2015 meeting of the American Epilepsy Society (AES) by Devinsky et al., 73 which included efficacy assessments for 261 children and young adults (mean age 11.8 years, median baseline convulsive seizure rate 31 seizures/28 days) with a variety of treatment-resistant epilepsies and treated for at least 3 months. The most common diagnoses were Dravet syndrome (n = 44; 17%) and Lennox-Gastaut syndrome (n = 40; 15%). Cannabidiol treatment began with doses of 2-5 mg/kg in two daily divided administrations titrated to intolerance or a target of 25 mg/kg/day. A subgroup was allowed to increase the dose to 50 mg/kg/day. Patients had a 4-week baseline and kept a diary of countable motor seizures. There was a 48.8% median reduction in the convulsive seizure rate among all patients and 52.3% in Dravet syndrome patients. Atonic seizures were reduced by a median of 71.1% among patients with Lennox-Gastaut syndrome. Seizure freedom was reported in 9% of all patients and 13% in Dravet syndrome patients for weeks 8-12. Patients taking clobazam showed a higher treatment response, with a median reduction in convulsive seizures of 56.4% versus 35% for those not taking clobazam at week 12. However, the effect of clobazam co-therapy was not observed in the Dravet syndrome and Lennox-Gastaut syndrome groups, where 53% had a ≥50% seizure reduction with clobazam versus 54% without clobazam. 73 The first randomized, double-blind, placebo-controlled study of cannabidiol in Dravet syndrome has been recently completed, and preliminary results have been reported. 74 The trial compared 20 mg/kg cannabidiol (n = 61) versus placebo (n = 59) added to preexisting AED treatment in a prospective, randomized, doubleblind comparison with a 4-week baseline and 14-week treatment (2-week dose escalation and 12-week maintenance period) parallel design. The primary end point was the median percent reduction in tonic-clonic, tonic, clonic or atonic seizures. The results showed a significant reduction favoring cannabidiol (39% vs. 13%, p = 0.01). A series of sensitivity analyses supported this result. The difference between cannabidiol and placebo was noted during the first month of therapy and was sustained for the remainder of the trial.
The primary results of a second prospective, doubleblind, multicenter, placebo-controlled study conducted in patients with Lennox-Gastaut syndrome were reported on 27 June 2016 as a press release. 75 There were 86 patients randomized to 20 mg/kg cannabidiol added to preexisting AED treatment versus 85 patients on placebo, with a 4-week baseline followed by a 14-week treatment period, which included a 2-week dose escalation period. The primary outcome was the percent change in monthly atonic, tonic, or tonic-clonic seizures, which led to or could have led to fall or injury during the 14-week treatment period. The cannabidiol group showed a 44% reduction in monthly drop seizures, whereas placebo showed a 22% reduction (p = 0.0135).
Cannabidiol has now been reported to have efficacy in well-controlled studies of Dravet syndrome and LennoxGastaut syndrome. Additional controlled trials in the same epilepsy syndromes are expected to complete in 2016 and 2017, respectively.
Tolerability and adverse effect profile
In the Epidiolex development program, cannabidiol appeared to be well tolerated, and the evolving safety profile shows consistency in the extended access programs and the controlled trials.
The first published extended access program report included 214 patients enrolled and 162 patients (76%) who had at least 12 weeks of follow-up after the first dose of adjunctive cannabidiol were included in the safety and tolerability analysis, with 137 patients (64%) being included in the efficacy analysis. 72 AEs were not well correlated with dose, although the patients taking >15 mg/kg were more likely to report diarrhea and related effects such as weight loss than those taking ≤ 15 mg/kg. A few patients took up to the maximum of 50 mg/kg/day, but all reduced their dose by week 12. The safety group in this report was taking a mean dose of 22.9 mg/kg/day at week 12. AEs occurring in ≥10% of patients included somnolence, diarrhea, convulsions, decreased appetite, and fatigue. Mild elevations of hepatic transaminases were reported (11%), although one patient discontinued for liver enzyme abnormalities.
The poster presentation of a larger cohort by Devinsky et al. 73 included safety data among 313 patients in the extended-access program. AEs occurring in ≥10% of patients included somnolence (23%), diarrhea (23%), fatigue (17%), convulsions (17%), and vomiting (10%). Discontinuations due to an AE were 4%. A serious AE occurred in 106 (34%) of the patients. There were seven deaths, none of which were deemed to be treatment related. There were 16 patients with serious AEs reported as treatment related (5%), including diarrhea, altered liver enzymes, and SE/convulsions (four each) as the most common.
Similar AEs were noted in the well-controlled Dravet and Lennox-Gastaut syndrome trials. In the Dravet syndrome trial, AEs occurring in ≥10% of cannabidiol-treated patients were somnolence, diarrhea, decreased appetite, fatigue, pyrexia, vomiting, and lethargy. AEs were mostly mild or moderate in patients on cannabidiol. Ten patients had serious AEs on cannabidiol, whereas three had serious AEs on placebo. Discontinuations due to AEs were reported for eight patients on cannabidiol and one patient on placebo. A similar profile was reported in the recently completed study in Lennox-Gastaut syndrome, where AEs reported in ≥10% of cannabidiol-treated patients were diarrhea, somnolence, decreased appetite, pyrexia, and vomiting. AEs recorded on cannabidiol treatment were mostly mild or moderate. Twenty patients on cannabidiol experienced a serious AE compared with four patients on placebo. Discontinuations due to AEs were reported for 12 patients on cannabidiol compared with one patient on placebo. There was one death in the cannabidiol group, which was deemed to be unrelated to treatment.
The long-term safety of cannabidiol will be informed by the hundreds of patients in both the extended-access program and the open-label extension that follows the double-blind studies that are ongoing. The maximum dosing in those trials is up to 50 mg/kg in the extended access program and 30 mg/kg in the extension studies.
Planned studies
In addition to the ongoing programs for Dravet and Lennox-Gastaut syndrome, a placebo-controlled phase III trial for the treatment of seizures associated with TSC has recently been initiated, and a phase III placebo-controlled trial for the treatment of infantile spasms is planned for the end of 2016. Other indications in epilepsy are being considered for future studies.
Cannabidivarin
Introduction
Cannabidivarin is a phytocannabinoid and an active constituent of Cannabis sativa. Cannabidivarin has shown antiepileptic activity in models of seizures, both in vitro and in vivo. It is now being investigated in a phase II trial for focal seizures in adults.
Pharmacology
Anticonvulsant profile
Cannabidivarin inhibits epileptiform activity in vitro and shows efficacy in vivo in animal models of seizures. The activity of cannabidivarin in various in vivo and in vitro seizure and epilepsy models has been described in the EILAT XII Progress Report. 3 Briefly, antiepileptiform activity of cannabidivarin has been observed in the 4-aminopyridine model at concentrations ≥1 lM and in magnesium-free models at concentrations ≥10 lM, using extracellular recordings from acute rat hippocampal slices on a multi-electrode array. 76 The anticonvulsant activity of cannabidivarin has been confirmed in three acute behavioral models of seizures, including (1) the mouse MES model of generalized seizures (30 mA; 100 Hz; 200 msec), in which cannabidivarin (≥50 mg/kg, i.p.) significantly reduced tonic convulsions, and hindlimb and forelimb extension; (2) the mouse audiogenic model of generalized seizures, in which cannabidivarin significantly reduced the incidence of tonic convulsions in a dose-dependent manner, with a median effective dose (ED 50 ) of 64 mg/kg, i.p. 77 ; and (3) the acute PTZ rat model of generalized seizures, in which cannabidivarin (200 mg/kg, i.p.) significantly reduced the incidence of tonic-clonic seizures, median seizure severity and seizure-related mortality. Furthermore, in the latter model, cannabidivarin increased latency to seizure onset and number of animals that remained seizure-free. 76 These effects were retained in a subsequent study, where cannabidivarin was coadministered with either ethosuximide (60-175 mg/kg, i.p.) or valproic acid (50-250 mg/kg, i.p.), thus showing that cannabidivarin (200 mg/kg, i.p.) does not functionally antagonize the anticonvulsant actions of ethosuximide or valproic acid. 76 Alongside behavioral studies in acute seizure models, a study was undertaken using the PTZ model of acute generalized seizures where molecular markers of seizures were examined. Here, cannabidivarin at a dose of 400 mg/kg per os (p.o.) significantly reduced median seizure severity and suppressed seizure-related change to increases in Fos, Egr1, Arc, Ccl4, and BDNF. 78 The static beam and forelimb grip strength assays were undertaken to assess the effects of cannabidivarin following acute administration (50-200 mg/kg, i.p.) in rats, where there were no significant effects on any of the parameters tested. This contrasts with valproate (125-350 mg/kg, i.p.), which demonstrated a dose-dependent increase in the number of foot slips observed and the distance traveled on the static beam. 76 These motor function tests confirmed that the anticonvulsant effects of cannabidivarin (≤200 mg/kg) in acute models of seizures are due to genuine antiseizure properties and not to suppression of motor function.
Mechanism of action
The precise mechanism by which cannabidivarin exerts anticonvulsant effects is unknown and is currently under investigation. Cannabidivarin possesses neither affinity nor function at cannabinoid type 1 (CB1) or type 2 (CB2) receptors, 78 and it has no significant effect on other components of the endocannabinoid system 76 at physiologically relevant concentrations. Cannabidivarin can exert effects at transient receptor potential (TRP) channels in vitro to modulate intracellular calcium, 79, 80 but interaction with these targets is unlikely to confer antiepileptic activity.
Toxicology
Preclinical safety pharmacology (cardiovascular, respiratory, hERG channel, and Purkinje fiber studies), genetic toxicology (in vivo and in vitro), reproductive toxicology, and chronic, repeat-dose toxicology studies have been conducted. No target-organ toxicity has been observed in chronic studies. Genotoxicity studies covering relevant genotoxicity end points showed no evidence of mutagenic activity.
Pharmacokinetics and metabolic profile
A formal phase I single-and multiple-dose human pharmacokinetic study in healthy adult volunteers has been completed but not yet been published (GW Pharmaceuticals, data on file, unpublished). Single oral doses of 25, 75, 200, 400, and 800 mg were given, and multiple doses of 800 mg daily were given once daily over 5 days. There was also a single dose of 5 mg of an intravenous formulation. Both oral and intravenous cannabidivarin were well tolerated. The 7-hydroxy-and 6-hydroxy-metabolites were found to appear rapidly in the systemic circulation after both oral and intravenous dosing. Pharmacokinetic analysis showed that cannabidivarin peak plasma concentration (C max ) and area under the plasma concentration-time curve (AUC) were dose proportional between the 200 and 800 mg dose range.
Drug interactions
A phase II study evaluated potential induction or inhibition of cannabidivarin clearance by concomitant AEDs in patients with focal seizures aged 18-65 years (GW Pharmaceuticals, data on file, unpublished). In part A of that study, patients were randomized into three categories: concomitant inducers, inhibitors (valproic acid), or neither. Preliminary data did not identify differences in pharmacokinetics among the three groups, and indicated that no cannabidivarin dose adjustment based on type of co-medication was needed for part B of the study. Part B is ongoing in patients taking cannabidivarin as adjunctive therapy for uncontrolled focal seizures.
Tolerability and adverse effect profile
The preliminary data from the phase I study in healthy volunteers showed little difference in AEs reported between those taking cannabidivarin and those taking placebo after the single, multiple, or intravenous doses. There were no serious AEs and no discontinuations for AEs. The study also showed no effect on vital signs or ECG recording extended telemetry. Nearly all AEs were mild and none were severe. Tolerability was also good in part A of the phase II trial, and again there were no serious AEs or discontinuations for AEs.
Planned studies
The ongoing part B of the phase II study in adults with focal seizures is aimed at assessing the efficacy and safety of cannabidivarin for inadequately controlled focal seizures in male and female patients aged 18-65 years and taking 1-3 concomitant AEDs. The study is double-blind and placebo-controlled and includes a 4-week baseline and 2-week titration, starting with 400 mg, b.i.d., titrating to 800 mg, b.i.d. Patients continue on the target dose for 6 weeks and then follow a 12-day taper. The primary end point is the percent change from baseline to the end of treatment in focal seizure frequency in subjects taking cannabidivarin compared with placebo. Further studies in focal or generalized seizures will be considered after the outcome of part B of the phase II study. Other studies in epileptic syndromes and conditions comorbid with epilepsy are being considered. 
2-Deoxy-D-Glucose
Introduction
2-Deoxy-D-glucose is currently in preclinical development for the treatment of epilepsy and traumatic brain injury (TBI). 2-Deoxy-D-glucose differs from normal glucose by removal of an oxygen atom at position 2. Radiolabeled 18 F-2-deoxy-D-glucose has been used for decades as a positron-emitting glucose analogue for measurement of glucose utilization by PET.
2-Deoxy-D-glucose undergoes activity-dependent uptake into cells through glucose transporters, and is then phosphorylated to 2-deoxy-D-glucose-6-phosphate, which unlike glucose-6-phospate cannot undergo isomerization to fructose-6-phosphate, thereby preventing subsequent steps of glycolysis. By preventing subsequent steps of glycolysis, 2-deoxy-D-glucose is a glycolytic inhibitor. The activitydependent accumulation of radiolabeled 18 F-2-deoxy-D-glucose in cells in response to metabolic demand and uptake enables use of 2-deoxy-D-glucose for measurement of cellular and tissue glucose utilization. The anticonvulsant and disease-modifying antiepileptic properties of 2-deoxy-Dglucose, and more generally glycolytic inhibition and reduced flux in the glycolytic pathway, were initially identified during investigations of mechanisms underlying the efficacy of the ketogenic diet, which is a diet incorporating isocaloric substitution of fats and proteins for carbohydrates. Reintroduction of carbohydrates in patients on the ketogenic diet who have achieved seizure control rapidly results in loss of antiseizure effect, suggesting that reduced glycolytic flux contributes to favorable actions of the diet, and implicating glycolytic inhibition as a mechanism of the anticonvulsant actions of 2-deoxy-D-glucose.
Pharmacology
Anticonvulsant profile
In addition to the effects of 2-deoxy-D-glucose in animal seizure and epilepsy models (see Bialer et al. 3 for review and references), 2-deoxy-D-glucose at concentrations of 5-10 mM in hippocampal slices has little or no effect on synaptic and network properties under normal conditions, but reduces the increase in spontaneous excitatory postsynaptic currents (sEPSCs) observed in CA3 neurons exposed to elevated [K + ] o . These concentrations also reduce epileptic field bursts in CA3 evoked by 7.5 mM [K + ] o , 50-100 lM 4-aminopyridine, and 10 lM bicuculline. 2-Deoxy-D-glucose (5-10 mM) also reduces spontaneous inhibitory postsynaptic currents (sIPSCs), but to a lesser degree than sEPSCs, thereby resulting in a net overall decrease in network excitatory activity during conditions of increased overall activity. 81 The actions of 2-deoxy-D-glucose appear to be presynaptic and involve reduction in the frequency but not the amplitude of miniature excitatory postsynaptic currents (mEPSCs). 81 The cellular actions of 2-deoxy-D-glucose are accompanied by acute anticonvulsant effects in multiple experimental in vivo models of seizures and epilepsy. In the mouse in vivo 6 Hz model, 2-deoxy-D-glucose acutely protected against seizures evoked by 6 Hz 22 mA corneal stimulation at doses of 75-300 mg/kg, i.p., with an ED 50 of 79.7 mg/kg. The time to peak action was 15 min at a dose of 75 mg/kg, i.p., and 1 h at a dose of 100 mg/kg i.p. 2-Deoxy-D-glucose protected against audiogenic seizures evoked in Frings mice 2 h after administration of 220-250 mg/kg, i.p. The ED 50 was 206.4 mg/kg, and the time to peak effect was 2 h at these doses. 2-Deoxy-D-glucose also demonstrated evidence of anticonvulsant activity against seizures evoked by PTZ at 30 min after administration at doses of 200-400 mg/kg, i.p., and 50-400 mg/kg, p.o., but overall the results were not sufficient to calculate an ED 50 or a time to peak effect. There was no protective effect of 2-deoxy-D-glucose against MES in rats when tested 15 min to 4 h after administration of 100-200 mg/kg, p.o. 82 2-Deoxy-D-glucose also reduces the latency to seizures evoked by pilocarpine and kainic acid. 83 In addition to acute in vivo anticonvulsant actions, 2-deoxy-D-glucose displays in vivo chronic "disease-modifying" antiepileptic effects against progressive effects of repeated seizures evoked by kindling. Administration of doses of 37.5-50 mg/kg 30 min prior to perforant path stimulation results in twofold slowing of progression of repeated seizures evoked by perforant path or olfactory bulb kindling. 82, 84 The effects on kindling progression have been observed when 2-deoxy-D-glucose was administered immediately after, and approximately 10 min after, evoked seizures. 85 This postseizure administration effect is most likely based on enhanced activity-dependent postictal delivery of 2-deoxy-D-glucose into those brain regions with increased energy demand as a consequence of the seizure, as 18 F-2-deoxy-D-glucose PET demonstrated that increased glucose utilization persists for about 15 min after seizures. This novel property of 2-deoxy-D-glucose based on delivery by auto-regulation of cerebral blood flow in response to regional metabolic and energetic demand represents a potential opportunity for "postseizure" anticonvulsant administration for the treatment of seizure clusters and SE.
Other pharmacologic properties
Both magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) studies as well as behavioral studies in experimental models of TBI have provided evidence that 2-deoxy-D-glucose has neuroprotective effects, and favorably modifies long-term adverse consequences of experimental TBI in rodents. MRI and DTI studies have demonstrated that 2-deoxy-D-glucose reduces progression of structural damage after initial injury induced by controlled cortical impact (CCI) in Sprague-Dawley rats, and in unique strains of rats bred for susceptibility or resistance to kindling progression evoked by perforant path stimulation of the hippocampus referred to, respectively, as Perforant Path Kindling Susceptible (PPKS) rats, or Perforant Path Kindling Resistant (PPKR) rats. [86] [87] [88] [89] Behavioral studies in the PPKS and PPKR strains have demonstrated that the kindling-susceptible PPKS strain is more vulnerable to adverse alterations in fear conditioning learning and fear-related memory after CCI than kindling-resistant PPKR and outbred strains. 90 2-Deoxy-D-glucose favorably reduces abnormal adverse fear learning and preserves memory function when administered acutely after experimental TBI induced by CCI in PPKS rats. 90 2-Deoxy-D-glucose also protects against secondary damage progression after CCI. Secondary progression refers to the cascade of evolving processes of progressive structural brain damage that continues for weeks and months following initial brain injury. After initial direct mechanical shearing/tearing/compression injury accompanied by edema, hemorrhage, and ischemia with auto-regulatory dysfunction and acute excitotoxicity, a continuing sequence of apoptotic and inflammatory processes contribute to evolving damage leading to progressive atrophy and brain parenchymal loss for many months after initial injury. After CCI-induced injury in rodents, 2-deoxy-Dglucose (40 mg/kg at the time of injury and 250 mg/kg/ day for 2 weeks) reduced progressively increasing ventricle volume, progressive hippocampal diffusion abnormalities, and hippocampal and corpus callosum anisotropy in serial in vivo MRI and DTI studies at 1-6 months after injury. Because treatment with 2-deoxy-D-glucose did not modify the extent of the initial injury, these observations demonstrate neuroprotective actions against secondary damage progression. 87 Functional neuroprotection against adverse long-term behavioral and cognitive abnormalities by treatment with 2-deoxy-D-glucose at the time of initial injury include therapeutic effects on fear learning and preservation of memory after CCI. Behavioral studies using conventional fear-conditioning paradigms demonstrated that 2-deoxy-D-glucose (40 mg/kg at the time of injury and 250 mg/kg/day for 2 weeks) reduced adverse fear-conditioning learning observed in PPKS but not PPKR rats at 1 month after CCI and preserved fearcontext spatial memory at 6 months after CCI. 90 These observations are potentially relevant to therapeutic effects on cognitive and affective sequelae of severe TBI such as posttraumatic stress disorder, as well as potential consequences of repeated mild TBI such as serial concussions and chronic traumatic encephalopathy. Ongoing preclinical studies are investigating if treatment with 2-deoxy-D-glucose at the time of injury reduces or prevents emergence of generalized spike-wave discharges, which are observed in PPKS rats but not PPKR rats after CCI, 91 and are potentially relevant as a model of rodent posttraumatic epilepsy.
In normal human volunteers, administration of 2-deoxy-D-glucose at a dose of 40 mg/kg, i.v., rapidly induced regional increases in cerebral blood flow in cingulate gyrus, sensorimotor cortex, superior temporal cortex, occipital cortex, basal ganglia, limbic system, and hypothalamus. 92 This enhanced blood flow is likely to complicate assessments of seizure-onset latencies when 2-deoxy-D-glucose is co-administered with chemoconvulsants in animal models, as was observed when 2-deoxy-Dglucose was coadministered with intravenous PTZ or kainic acid, and mildly shorter latencies to seizures were interpreted as a proconvulsant effect. 93 
Toxicology
Preclinical toxicology including three studies in F344 and Sprague-Dawley rats and two studies in beagle dogs has demonstrated that 2-deoxy-D-glucose induces species-specific, dose-dependent, reversible cardiac toxicity consisting of cardiac myocyte vacuolation with features consistent with autophagy. These observations confirmed previous studies reporting similar cardiac myocyte vacuolation during chronic administration of 2-deoxy-D-glucose at doses of 0.25-0.4% of dietary intake in rats. 94 There were no adverse cardiac effects of 2-deoxy-D-glucose during 28 days of administration across a range of doses in beagle dogs, and the dose-dependent cardiac myocyte vacuolation in rats was reversible with a 14-day recovery period. 95 The dose-dependent, reversible cardiac myocyte vacuolation has histologic features consistent with autophagic processes rather than necrosis. Dose-dependent reversible myocyte vacuolation observed with 2-deoxy-D-glucose treatment may reflect the dependence of cardiac energetics in the rat on glycolytic metabolism, as both the brain and heart are the organ systems that significantly depend on glycolytic metabolism for support of physiologic activity.
In preclinical toxicology studies, the development and resolution of cardiac myocyte vacuolation during treatment with 2-deoxy-D-glucose in rats was tracked by twofold elevation of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) compared to normal controls, and was observed after 7 days of treatment with 2-deoxy-D-glucose prior to development of myocyte vacuolation at high-dose levels, suggesting the potential utility of NT-proBNP as a predictive cardiac biomarker for 2-deoxy-D-glucoseinduced cardiac toxicity. Tolerability and adverse effect profile 2-Deoxy-D-glucose given as adjuvant therapy for cancer in a phase I/II trial was found to be well tolerated with dose escalation up to 64 mg/kg/day, p.o., for 5-8 weeks. 98, 99 Higher doses were associated with QTc prolongation, and in a study in patients with prostate cancer, dose-limiting reversible toxicity consisting of grade 3 asymptomatic QTc prolongation was also observed in two patients at a dose of 60 mg/kg, p.o. 97 In the same study, however, QTc prolongation was not observed at doses of 45 mg/kg.
Planned studies
Pending completion of preclinical toxicology studies, an initial safety and tolerability clinical trial of 2-deoxy-D-glucose is anticipated including cardiac monitoring with NTproBNP, high sensitivity troponins, and continuous QTc monitoring. Potential indications include the treatment of refractory epilepsy patients with frequent focal or generalized seizures, patients with Lennox-Gastaut syndrome, the treatment of seizure clusters and SE, and use in combination with device therapies. Preclinical studies are ongoing to assess the potential role of 2-deoxy-D-glucose to prevent long-term sequelae of TBI.
Everolimus
Paolo Curatolo
Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University Hospital, Rome, Italy
Introduction and rationale for development
Everolimus is a selective inhibitor of the mammalian/ mechanistic target of rapamycin (mTOR) pathway, developed initially as an antitumor agent and then approved for the treatment of several types of cancer. More recently, everolimus has been approved for the treatment of patients with tuberous sclerosis (TSC) who have subependymal giant cell astrocytomas and renal angiomyolipomas. 100 mTOR overactivation has been observed in different conditions, grouped under the term "mTORopathies," which include focal cortical dysplasia, TSC, hemimegalencephaly, and ganglioglioma. 101 All these disorders share common histopathologic characteristics such as cortical dyslamination, enlarged and dysplastic neurons, and astrogliosis, as well as a range of clinical features such as early onset refractory seizures.
mTOR is a serine/threonine protein kinase that exerts a key role in a wide spectrum of crucial cellular processes, such as cell growth regulation, development, and proliferation to adaptive immune function, and integrates key information from nutrients, growth factors, cytokines, and hormones.
102 mTOR forms two different complexesmTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2)-with the former being sensitive to mTOR inhibitors and regulating the activity of downstream targets responsible for cell growth, enhanced translation, angiogenesis, transcription, and inhibition of autophagy.
103 mTOR signaling also plays a significant role in CNS developmental processes, such as axon guidance, dendritic development and spine morphogenesis, and synaptic plasticity. 102, 104 mTOR dysregulation has been implicated in several genetic and acquired models of epileptogenesis, including TBI, hypoxic-ischemic damage, temporal lobe epilepsy, and SE. 103 Hyperactivity of this pathway leads to global disturbances of brain architecture and alteration of excitation/ inhibition of neurotransmission, suggesting that the mTOR pathway could be a potential novel target for epilepsy treatment.
Pharmacology
Anticonvulsant profile
In preclinical studies, mTOR inhibitors showed not only an antiseizure effect, but also an antiepileptogenic potential, being able to prevent or delay the onset of seizures. In a TSC1 GFAP knockout mouse model, characterized by seizure onset after about 3 weeks of life and progressive worsening up to premature death, sirolimus (rapamycin) was administered before or after seizure onset. 105 Early treatment with sirolimus could prevent seizure onset and premature death, and reverse astrogliosis and neuronal disorganization. 105 Late treatment after seizure onset led to a reduction in seizure frequency and prolonged survival. 105 Subsequent studies on different TSC mouse models confirmed these findings, and showed that sirolimus also caused restoration of cell size and myelination, suggesting that mTOR inhibition in TSC has disease-modifying potential. 102, 106 Sirolimus administered before SE could decrease neuronal cell death, neurogenesis, mossy fiber sprouting, and the development of spontaneous epilepsy, whereas late sirolimus treatment after SE blocked the chronic phase of mTOR activation and reduced mossy fiber sprouting, without any effect on neurogenesis and cell death. 107, 108 In mouse models of TBI, sirolimus demonstrated an antiepileptogenic action following TBI with reduced microglia activation, and reduced mossy fiber sprouting and subsequent posttraumatic epilepsy. 109, 110 Sirolimus also decreased the development of epileptiform activity following overactivation of the mTOR pathway due to neonatal hypoxic damage.
111,112
Epilepsia, 58 (2) Furthermore, chronic administration of sirolimus prevented seizure onset in a genetic rat model of absence epilepsy. 113 Mechanisms of action mTOR inhibition can exert antiepileptic effects by acting on voltage-and ligand-gated ion channels, neurotransmitter receptors, and signaling pathways, thereby modulating neuronal excitability. 103 After acute administration, the mTOR inhibitor sirolimus, which is structurally related to everolimus, has limited anticonvulsant effects. After chronic administration, however, sirolimus has been found to prolong mean open channel time of calcium and sodium channels and to reduce cortical excitability by increasing voltage-gated potassium channel Kv1.1 expression in cortical and hippocampal neurons. 114, 115 Chronic sirolimus administration also increases GABA receptor-mediated synaptic activity and reduces AMPA receptor surface expression. 116 In individual, not replicated studies, sirolimus has been reported to reduce aberrant mossy fiber sprouting, revert abnormal cell growth, and control neuroinflammation.
117-119
Toxicology
In animal models, everolimus has been found to cross the placenta, and even exposure below the therapeutic level determined embryo/fetotoxicity in rats, with increased mortality and lower fetal weight. 3 Systemic toxicity in young rats included reduced body weight gain and appetite, and delayed developmental milestones, with full or partial recovery after withdrawal. No mutagenic activity has been demonstrated. Chronic administration of everolimus did not identify any oncogenic potential in mice and rats up to the highest doses, corresponding, respectively, to 4.3 and 0.2 times the estimated clinical exposure. 3 
Pharmacokinetic and metabolic profile
Everolimus is an immunosuppressant macrolide bearing a stable 2-hydroxyethyl chain substitution at position 40 on the sirolimus structure. 120 Everolimus has greater polarity than sirolimus and was developed in an attempt to improve the pharmacokinetic characteristics of sirolimus, and particularly to increase hydrophilic properties and oral bioavailability that is only 15%. 120 C max was reached at a median time of 1 h after daily administration of 5 and 10 mg everolimus under fasting conditions or with a light fat-free snack in patients with cancer. A light-fat meal reduced AUC by 32% and C max by 42%. Food, however, did not appear to affect the postabsorption phase concentration-time profile.
3 Everolimus trough concentrations within individual patients were approximately dose-proportional. In normal volunteers, a high-fat meal reduced everolimus AUC by 22% and C max by 54%.
In a study in patients with TSC-related subependymal giant cell astrocytomas, the initial daily dose was 4.5 mg/m 2 of body surface area, subsequently titrated to attain a whole blood trough concentration of 5-15 ng/ml. 121 Trough everolimus concentrations demonstrate a good relationship with overall exposure, providing a reliable measure for therapeutic drug monitoring. 122 Because of its narrow therapeutic range, high interindividual pharmacokinetic variability, and established drug exposure-response relationships, everolimus fulfils the prerequisites for therapeutic drug monitoring to be clinically valuable. 122 In patients with tumors who received everolimus at the dose of 10 mg/day, about 20% of the drug concentration in whole blood was confined to plasma. Everolimus plasma protein binding is around 74% in healthy subjects. There are no clinical studies assessing everolimus distribution in the human brain. Six main metabolites of everolimus have been detected in human blood, but after oral administration, everolimus is the main circulating component. 3 The half-life of everolimus is about 30 h. Everolimus clearance normalized to body surface area was found to be higher in younger patients.
Drug interactions
Because everolimus is a CYP3A4 and P-glycoprotein substrate, its absorption and subsequent elimination may be influenced by medications that affect CYP3A4 and/or Pglycoprotein activity. 3 Coadministration of powerful CYP3A4 inhibitors, such as some antifungal, antiviral, and macrolide agents, can increase markedly everolimus blood concentration. Substances that are inducers of CYP3A4 or P-glycoprotein, such as rifampicin, corticosteroids, carbamazepine, phenytoin, and phenobarbital, may decrease blood everolimus concentrations by increasing everolimus metabolism or efflux from intestinal cells. 3 Because everolimus is a CYP3A4 inhibitor, caution should be exerted if everolimus is combined with CYP3A4 substrates having a narrow therapeutic index.
Efficacy data
A prospective trial to evaluate the safety and efficacy of everolimus on subependymal giant cell tumors enrolled 28 patients and followed them up for 6 months. 123 Sixteen of these patients also had ongoing seizures, which occurred daily in 27% of them. After 6 months of everolimus treatment, only 8% of patients had daily seizures, and beneficial changes in 24-h video-EEG studies were observed in terms of reduction of awake and asleep interictal activities. 123 The same group performed a phase I/II clinical trial evaluating the efficacy of everolimus in medically refractory TSCrelated epilepsy, and reported a >50% seizure frequency reduction in 12/20 patients. 124 Recently, two small case series of TSC patients with refractory epilepsy treated with everolimus reported a response rate of >50%. 125, 126 A phase III study (EXIST-3, an acronym for "EXamining everolimus In a Study of Tuberous sclerosis [TSC]") has been completely recently. EXIST-3 (clinicaltrials.gov, NCT01713946) was a three-arm, randomized, doubleblind, placebo-controlled study to evaluate the efficacy and safety of two trough-ranges of everolimus (3-7 and 9-15 ng/ml) given as adjunctive therapy in patients with TSC-related refractory seizures. The study included a prospective baseline during which patients completed a seizure diary for a total of 8 weeks. Patients were then randomized in a 1:1:1 ratio to (1) everolimus to attain a trough level of 3-7 ng/ml; (2) everolimus to attain a trough level of 9-15 ng/ml; or (3) placebo. Following randomization, patients entered a treatment phase, which started with a 6-week titration period followed by a maintenance period of 12-week duration. A total of 366 patients were randomized to everolimus low-exposure (n = 117), high-exposure (n = 130), or placebo (n = 119). The median percentage reduction in seizure frequency was significantly greater with everolimus 3-7 ng/ml (29.3%, p = 0.003) and 9-15 ng/ml (39.6%, p < 0.001) compared with placebo (14.9%). 127 The youngest patients (<6 years) achieved the highest response rates. The extension phase of EXIST-3 is currently ongoing.
Tolerability and adverse effect profile
AEs reported in ≥10% of patients in TSC studies included infections of the upper respiratory tract, increased cholesterol levels, and stomatitis. Less frequently reported, but still common (≥1/100 to <1/10) AEs were other infections, abnormalities in various hematology and biochemistry parameters, anorexia, headache, hypertension, gastrointestinal disorders, and mild skin changes. AEs were mostly mild and self-limited, and rarely led to discontinuation of treatment. Everolimus has also been reported to be a relatively safe therapeutic option for patients younger than 3 years. 128 In the EXIST-3 study, grade 3 or 4 AEs were reported with placebo versus everolimus low/high-exposure in 10.9% versus 17.9/23.8%. Serious AEs were reported in 2.5% versus 13.7/13.8%. 127 AEs led to treatment discontinuation in 1.7% versus 5.1/3.1%.
Ongoing clinical studies
There are currently several ongoing trials evaluating everolimus efficacy and tolerability in TSC-related epilepsy and its comorbidities, including neurobehavioral disturbances. 129 A pilot trial will evaluate the effects of everolimus on brain mTOR activity and cortical hyperexcitability in patients with focal cortical dysplasia and TSC who are undergoing brain surgery (clinicaltrials.gov, NCT02451696).
Fenfluramine HCl (ZX008)
Gail M. Farfel, Arnold Gammaitoni, and Brad Galer Zogenix Inc., Emeryville, California, U.S.A.
Introduction and rationale for development
Dravet syndrome is a rare and severe epilepsy syndrome that first presents in infancy and is refractory to conventional AEDs. Although the pathophysiology of Dravet syndrome is not well-understood, mutations in SCN1A, which codes for the a1 subunit of the voltage-gated sodium channel Nav1.1 in CNS neurons, are found in about 75-85% of Dravet syndrome patients. 130 Current treatment of Dravet syndrome usually involves multiple AEDs, including combination therapy with valproic acid, clobazam, topiramate, stiripentol, and others, 131 but despite the use of these multidrug regimens, four or more tonic-clonic seizures per month are reported to occur in 45% of patients, with at least one hospitalization for SE in the previous year in 33% of patients. 131 Thus, a clear need for new antiseizure medications for patients with Dravet syndrome still exists. (AE)-Fenfluramine HCl (ZX008) is being developed as an oral solution for add-on treatment of seizures in Dravet syndrome.
Pharmacology
Fenfluramine (3-trifluoromethyl-N-ethylamphetamine), a derivative of amphetamine, was originally developed as an appetite suppressant agent. Its anorectic activity is thought to be mediated through modulation of neuronal serotonin (5-HT) within the CNS, and specifically through effects at the 5HT 2C receptor. Fenfluramine disrupts neuronal vesicular storage of 5-HT resulting in its release, and has also been reported to inhibit neuronal 5-HT reuptake. 132 In addition, fenfluramine acts on norepinephrine transporters to increase the extracellular concentrations of norepinephrine in the cortex.
The mechanism responsible for the clinical efficacy of fenfluramine in the treatment of Dravet syndrome has not been established. Increases in CNS extracellular 5-HT levels and specific 5-HT receptor activation have been reported to provide antiseizure activity in animal models, although currently available serotonergic drugs have not demonstrated significant clinical benefit in patients with epilepsy.
A zebrafish model of Dravet syndrome has been described in which the zebrafish ortholog of the human SCN1A has been knocked down 133 or knocked out. 134 In this model, the characteristic seizure-like locomotor behavior of the larval zebrafish is attenuated in the presence of fenfluramine 133 and other compounds specifically targeting 5-HT receptor subtypes 1D, 2A, and 2C, with other 5-HT receptor subtypes also possibly playing a role. 134 
Toxicology
Studies completed to support the original marketing application for the treatment of adult obesity included acute and repeat-dose toxicology studies as well as reproductive and developmental studies in mice, rats, rabbits, and rhesus monkeys. 135 The primary findings in chronic toxicology studies in rats and dogs using doses up to 40 mg/kg/day (rats) or 20 mg/kg/day (dogs) were behavioral changes, with animals becoming "more quiet," as well as decreases in food consumption and body weight gain. Dogs also showed a slight decrease in blood pressure and decrease in heart rate. In general, the nature of the findings observed in these studies was consistent with the known pharmacology of (AE)-fenfluramine.
Because in Dravet syndrome fenfluramine will be administered to a pediatric population, Zogenix has completed a good-laboratory-practice (GLP) dose-range-finding study in juvenile rats and a 10-week GLP repeat-dose toxicology study in juvenile rats (starting on postnatal day 7). There were no findings in the dose-ranging study. The only finding in the 10-week study was eosinophilic globules in the nasal cavity, larynx, and lungs, which were not considered an adverse effect. There were no histopathologic findings in CNS or cardiac tissue and no behavioral changes were observed (Zogenix, data on file).
Genetic toxicology studies have been conducted to evaluate fenfluramine at current testing standards. Tests included the bacterial mutation test, a micronucleus test, and a Comet assay. The results of these studies showed no evidence of genetic toxicity (Zogenix, data on file).
The use of fenfluramine for the treatment of adult obesity has been associated with cardiac valvulopathy and pulmonary hypertension. 136, 137 Research on the mechanism of drug-induced cardiac valve disease has shown that cardiac valve thickening is a result of the mitogenic activity of 5-HT 2B receptors when they are stimulated by potent 5-HT agonists.
Pharmacokinetic and metabolic profile
In healthy volunteers, fenfluramine is quickly absorbed following oral dosing with C max occurring about 4 h after dosing. 138 The elimination half-life is about 20 h following a single dose for both the (+) and the (À)-enantiomer. The major metabolite of fenfluramine is norfenfluramine, which appears in plasma within 2 h of dosing and has a longer half-life of about 30 h. 138 The pharmacokinetics of fenfluramine have not been yet described for patients with Dravet syndrome.
In vitro metabolism studies have shown that fenfluramine is converted to its major metabolite norfenfluramine partially by CYP1A2, CYP2B6, and CYP2D6, with additional metabolism by CYP2C9, CYP2C19, and CYP3A4 (Zogenix, data on file). The main route of elimination of fenfluramine and its metabolites in humans is renal (>90%).
Drug interactions
Because the metabolism of fenfluramine and its major metabolite norfenfluramine is mediated by multiple CYP isoforms, interference with a single pathway (or CYP) is unlikely to cause significant changes in fenfluramine clearance. In vitro assessments of the CYP enzyme inhibition and the induction potential of fenfluramine and norfenfluramine have shown that fenfluramine and norfenfluramine are weak inhibitors of CYP2D6 and weak inducers of CYP3A4. Little or no effect of fenfluramine on CYP2D6 and CYP3A4 substrates is expected. In addition to pharmacokinetic interactions, there is the potential for pharmacodynamic interactions, notably serotonin syndrome, with other serotonergic drugs. Drug interactions of fenfluramine with other AEDs are currently being investigated in the ongoing development program.
Efficacy data
The initial reports of the successful use of fenfluramine for the treatment of refractory epilepsy were in the 1980s, with several case series published in pediatric patients with severe self-induced photosensitive epilepsy or other severe childhood epilepsies unresponsive to other treatments. 139 In addition, there have been other small studies and case series reporting an antiepileptic activity of fenfluramine, the most notable being summarized below.
In a 1996 case series, a cohort of 11 institutionalized patients with severe seizures refractory to common AEDs were treated with fenfluramine. 140 This group of patients had a mean age of 8 years (range 18 months to 15.5 years), and all demonstrated generalized tonic-clonic seizures despite treatment with one or more AEDs. Within 2 to 3 weeks after starting fenfluramine (0.5-1.0 mg/kg per day) seizure control improved, and during the observation period of between 3 and 8.5 years, seven patients became seizure-free, and the other four experienced >75% reduction in seizure frequency. In approximately 2001, after SCN1A testing and a closer investigation of clinical history, five of the patients in this case series were subsequently diagnosed with Dravet syndrome and were included in a long-term treatment cohort described below. 141 The antiseizure effectiveness of fenfluramine in patients with Dravet syndrome has been demonstrated in an ongoing 27-year observational study in Belgium. The patients (n = 21) have been divided into two cohorts, the "original" cohort being those patients who initiated treatment prior to April 2010 and were reported in a 2012 publication, 141 and the "new" cohort being those patients who initiated treatment after April 2010. The original cohort included 12 Dravet syndrome patients who had fenfluramine added to their current AED regimen, which included valproate in each patient, and topiramate and a benzodiazepine in six patients. 141 At the time of initiation of fenfluramine, the mean age of this cohort was 8 years (median = 7 years; range 1.3-16 years). The mean fenfluramine dose was 0.34 mg/kg/day (range, 0.12-0.90 mg/kg/day). Two patients withdrew from fenfluramine, one due to lack of efficacy and one who had become seizure-free during treatment and remained seizure-free during and after a temporary withdrawal of treatment due to a drug shortage. After a mean follow-up period of 11 years and 4 months (range 1-22 years), 7 of the 10 patients who remained in the study had been seizure-free for the previous year or longer, with 6 years and 7 months as the mean years of seizure freedom (range 1-19 years). One additional patient experienced a 75% decrease in the frequency of tonic-clonic seizures from 1 per week to 1 per month, and two patients did not respond to treatment. The 10 patients continued treatment with fenfluramine (mean dose 0.27 mg/kg/day, range 0.13-0.46 mg/kg/day) for five additional years. 142 Total observation time ranged from 6 to 27 years, with a mean of 16.1 years. Three patients were seizure-free during the entire 5-year observation period, and four additional patients experienced seizure-free intervals of at least 2 years.
The "new cohort" described above is a prospective, openlabel study of fenfluramine add-on therapy in patients with Dravet syndrome. 143 Nine Dravet syndrome patients were enrolled after April 2010 and received open-label add-on treatment with low-dose fenfluramine (5-10 mg per day; mean dose 0.24 mg/kg/day). Median treatment duration was 1.5 years (range 0.3-5.1 years). During the 90-day runin period prior to initiating low-dose fenfluramine treatment, the median frequency of major motor seizures (defined as tonic, clonic, tonic-clonic, atonic, and myoclonic seizures lasting >30 s) was 15.0 per month (range 0.4-39.7). Over the entire observation period, the median frequency of major motor seizures was reduced to 1.5 per month, and the median decrease was 75% (range 28-100%). Six of the nine patients had at least a 70% reduction in major motor seizures, and one subject was seizure-free for the entire treatment period.
Tolerability and adverse effect profile
The most common treatment-related AEs that have been observed in the two cohorts of patients with Dravet syndrome are mild-to-moderate somnolence, fatigue, and anorexia. No patients stopped fenfluramine due to tolerability issues. When marketed for the treatment of obesity in adults at 60-120 mg/day, the most common AEs were drowsiness, diarrhea, and dry mouth.
The use of fenfluramine for the treatment of adult obesity has been associated with cardiac valvulopathy and pulmonary hypertension. 136, 137 These cases occurred primarily in adult women, often in patients taking fenfluramine in combination with phentermine. 144 In one 1997 case series including 24 patients, the mean dose of fenfluramine associated with cardiac valvulopathy was approximately 56.5 mg/ day (range 20-220 mg/day), whereas the total number of prescriptions in the United States for fenfluramine and phentermine in 1996 was estimated to be approximately 18 million. 136 The risk of these serious AEs in a younger patient population being treated with lower doses of fenfluramine (maximum of 30 mg/day) has not yet been established and is being prospectively monitored in the ongoing studies. In these studies, no patient has presented with any clinical signs or symptoms of cardiac valvulopathy or pulmonary hypertension. In the original cohort, these examinations occurred over the past 8 years of treatment. Slight thickening of one or more cardiac valves on echocardiographic examination was observed in six patients at one or more time points of the study, but at the most recent examination slight thickening was detected in only two patients and without progression. 142 In the new cohort of patients, no valve abnormality has been observed at any assessment. 143 The efficacy and safety data from the ongoing open-label study of fenfluramine as add-on therapy for uncontrolled seizures in Dravet syndrome suggest that the benefit-to-risk relationship is different when the medication is used to treat seizures in Dravet syndrome as compared with treating adult obesity.
Planned studies
Zogenix is running three double-blind, randomized, placebo-controlled studies of add-on fenfluramine for the treatment of uncontrolled seizures in Dravet syndrome. In two identical studies, children and young adults will be randomized to placebo, fenfluramine 0.2 mg/kg/day, or fenfluramine 0.8 mg/kg/day after a run-in period and will be treated for a total of 14 weeks. In the third study, a similar design is employed, although all subjects are receiving stiripentol as a background AED. A long-term open-label extension study is also being conducted. Pharmacokinetics and drug-drug interactions of fenfluramine with other commonly used AEDs are being assessed in the randomized controlled studies and in a protocol with adult healthy volunteers.
them have been employed to treat a variety of CNS diseases including migraine, bipolar disorder, and neuropathic pain. However, the benefits of historical AEDs have been constrained by unintended CNS adverse effects. Combining proprietary breakthrough chemistry with Fluorinov Pharma and the National Institutes of Health's (NIH's) in vivo phenotypic screening strategy identified three completely novel candidate drugs, including FV-082, with preclinical safety and efficacy profiles superior to prototypical AEDs. FV-082 was elected by the NIH's Anticonvulsant Screening Program (ASP) as a promising candidate that received a comprehensive profile report (known as a "Red Book") detailing all generated biologic and comparative data, which is frequently used as the original source of publications as well as documentation for early discussions with the FDA and supporting evidence in submissions of Investigational New Drug (IND) applications.
Pharmacology
Anticonvulsant profile
FV-082 was screened across available in vitro and rodent seizure models at ASP, and was found to display a broad spectrum of antiseizure activity and a safety profile superior to valproic acid, gabapentin, and levetiracetam. FV-082 has an ED 50 of 20.1 AE 0.7 mg/kg (p.o.) in the rat MES test and 17.4 AE 0.6 mg/kg (i.p.) in the mouse 6 Hz model. FV-082 prevented seizures induced by sound in the audiogenic seizure-susceptible Frings mouse model with an ED 50 value of 13.0 AE 2.0 mg/kg (i.p.). In addition, FV-082 displayed significant efficacy in the electrically induced corneally kindled mouse, kindled rat and hippocampal kindled models. It is notable that FV-082 was also found to limit seizure spread and elevate seizure threshold in the mesial temporal lobe epilepsy (MTLE) acute model of pharmacoresistant epilepsy. The anticonvulsant pharmacology suggests applicability for treating multiple types of seizures, such as generalized focal, generalized tonic-clonic, and myoclonic seizures, at dose levels that confer a favorable safety margin in preclinical models.
Other pharmacologic properties
A single dose of FV-082 showed robust efficacy in models of neuropathic pain such as spinal nerve injury (50 mg/kg, i.p.) and formalin inflammatory pain (71 mg/kg, i.p.), without any signs of sedation.
Mechanism of action
Mechanistically, broad ion channel profiling in combination with a Cerep-Panlabs broad profiling screen (10 lM) across 100 known G-protein-coupled receptors, ion channels, transporters, and enzyme targets suggest that several mechanisms contribute to the pharmacologic profile of FV-082, but that no single mechanism is likely to be a major contributor. In fact, in whole-cell patch-clamp recordings, FV-082 inhibited voltage-gated Na + channel Nav1.8, and the Cerep-Panlab panel indicated that FV-082 interacted with androgen receptor and human recombinant enzyme monoamine-oxidase B (MAO-B).
Toxicology
Safety assessment of FV-082 suggests no interaction with the major CYP isoenzymes when tested at concentrations up to 500 lM and no functional hERG activity when tested at concentrations up to 20 lM. Furthermore, in acute toxicity studies, FV-082 exhibited no adverse effects when given orally and intravenously in rats and mice, with a maximally tolerated dose >600 mg/kg in mice (i.p.) and rats (p.o.). A large protective index; that is, ratio between median toxic dose (TD 50 ) for behavioral impairment in the rat and MES ED 50 for protection against MES-induced tonic extension seizures in the rat (TD 50 / MES ED 50 ) of >34-fold was observed following oral administration. In addition, the maximal tolerated dose was found to be >1,000 mg/kg (p.o.) in mice and rats and >120 mg/kg (p.o.) in dogs. Furthermore, 14-day Irwin test and acute toxicity studies at oral doses of 200 and 400 mg/kg in rat suggest that FV-082 is well tolerated. A telemetry cardiopulmonary safety study, under GLP conditions, following oral dosing of FV-082 in conscious female beagle dogs showed no evidence of cardiopulmonary pharmacologic adverse effects following a single oral dose up to 120 mg/kg. FV-082 does not have the narrow CNS therapeutic index in animals of many AEDs and displays a considerably broader CNS therapeutic index than many of the currently available AEDs.
Pharmacokinetics
In vivo pharmacokinetic studies in mouse, rat, and dog at a dose of 20 mg/kg revealed that FV-082 has high oral bioavailability (100%, 84%, and 34% in mouse, rat, and dog, respectively), with half-life values of 1, 3, and 4 h in each species, respectively, after oral dosing. In addition, drug exposure as measured by C max and AUC was shown to be linear with dose.
Planned studies
A 28-day repeated oral dose toxicity study of FV-082 under GLP conditions in Sprague-Dawley rats is ongoing. The purpose of the study is to determine the potential toxicity and toxicokinetics of FV-082, when administered orally to rats daily for a 28-day period. This study also assesses the progression or regression of any effects following a 14-day treatment-free recovery period for the control and high-dose groups. A convenient and cost-effective manufacturing process for FV-082 has been developed allowing for access to multikilogram scale synthesis. Based on the promising preclinical data outlined above, clinical investigations are being planned. Ganaxolone *Julia Tsai, †Michael Saporito, *Jaakko Lappalainen, and *Albena Patroneva *Marinus Pharmaceuticals, Inc, Radnor, Pennsylvania, U.S.A.; and †Pharmaceutical Consultant, Exton, Pennsylvania. USA.
Introduction and rationale for development
Ganaxolone (3a-hydroxy-3b-methyl-5a-pregnan-20-one) is a CNS-selective, positive allosteric modulator of the GABA A receptor. It is a 3b-methylated synthetic analog of the endogenous progesterone metabolite, allopregnanolone. Ganaxolone was designed to have the same modulatory effects at GABA A receptors as allopregnanolone without activation of nuclear (classical) progesterone receptors, enabling chronic dosing. Ganaxolone differs from other GABA agents by interacting with both synaptic and extrasynaptic GABA A receptors and at binding sites distinct from benzodiazepines. Seizure protection has been demonstrated with ganaxolone in a broad range of animal seizure models, 12, 145 and unlike other GABA A -receptor modulators, ganaxolone does not show tolerance to anticonvulsant activity.
The current indications for ganaxolone include programs in focal seizures and orphan indications including SE, genetic epilepsies, and anxiety and attention in fragile X syndrome.
Ganaxolone is being developed in three different dose forms (intravenous, capsule, and liquid suspension) to maximize therapeutic reach to adult and pediatric patients in both acute and chronic care settings. The intravenous formulation was the most recent addition, and it is intended to complement oral dose forms for patients in SE. The current treatment paradigm for SE is initial treatment with benzodiazepines to control SE followed by standard AEDs such as phenytoin or valproic acid, and then administration of general anesthetics such as propofol. Patients with SE become progressively refractory to treatment over time. Moreover, >30% of patients with SE are resistant to aggressive benzodiazepine administration. Thus, therapeutics that block treatment-resistant forms of SE are needed. The availability of the oral formulation of ganaxolone could allow for continuity of care as patients recovering from SE transition from hospital to outpatient settings.
Pharmacology
Ganaxolone binds with high affinity to both synaptic and extrasynaptic GABA A receptors. The preclinical antiseizure profile has been described previously and the reader is referred to Bialer et al. 3 for a summary and references. The recent addition of the intravenous formulation triggered additional preclinical studies in animal SE models. SE can be modeled in rats by administration of lithium and pilocarpine. Animals become refractory to benzodiazepine treatment if initiated ≥15 min after seizure onset, thus modeling a treatment-resistant form of SE. Ganaxolone was shown to be efficacious in an EEGbased rat model of treatment-resistant SE. Intravenous ganaxolone (12 or 15 mg/kg) administered at 15 and 60 min after SE onset showed a durable 5-h response. In comparison, the duration of effect of ganaxolone was longer than what was seen with positive control by allopregnanolone (Marinus Pharmaceuticals, data on file). Ganaxolone was also efficacious in a behavioral model of treatment-resistant SE. Intravenous ganaxolone halted SE and produced a dose-dependent reduction in seizures associated with SE when administered at three different doses over four separate time points after the first observed convulsive seizure. Significant activity was observed at a dose of 6 mg/kg and maximal protection at dose levels between 9 and 12 mg/kg. Intravenous ganaxolone promoted survival at rates similar to those observed with administration of allopregnanolone as measured at 24 h after SE onset in rats.
Toxicology
Preclinical safety pharmacology and toxicology testing, including reproductive toxicology, has been conducted with ganaxolone at doses relevant for chronic human administration. No evidence was found to indicate functional or anatomic adverse effects in blood, liver, kidney, or gastrointestinal systems associated with either singleor multiple-dose treatment with ganaxolone from studies in rats (up to 6 months) and dogs (up to 1 year). The intravenous formulation of ganaxolone has been tested in GLP preclinical toxicology studies and found to be safe and well tolerated with administration up to 14 days as a continuous infusion at doses up to 84 mg/kg for male and 42 mg/kg for female rats, and as bolus + infusion administration at doses of 54 mg/kg for male rats and 36 mg/kg for female rats. In addition, no end-organ toxicities have been identified in preclinical safety pharmacology studies, and no evidence of end-organ toxicity has been identified from human clinical trials. In reproductive toxicology studies, ganaxolone did not cause any malformations of the embryo or fetus in rats or mice and did not significantly affect the development of offspring. No changes in sperm parameters were found (Marinus Pharmaceuticals, data on file).
Pharmacokinetic and metabolic profile
Ganaxolone is lipophilic, and a high-clearance drug, available in oral suspension and capsules. The intravenous formulation of ganaxolone will enter clinical testing in 2016. Ganaxolone is metabolized primarily by the CYP3A family of liver enzymes. Steady state is achieved within 48-72 h using capsules b.i.d. at total daily doses of 400 through 2,000 mg per day. The half-life after intake of the capsule is 7-10 h. C max and AUC (0-12 h) at steady-state are close to dose-proportional at lower doses up to 900 mg b.i.d. and subproportional at higher doses (Marinus Pharmaceuticals, data on file).
Drug interactions
Ganaxolone has low interaction potential with other drugs at several multiples of observed human ganaxolone levels. An interaction study with midazolam indicated that ganaxolone is not a CYP3A4 inhibitor and with minimal potential to induce CYP3A4. (Marinus Pharmaceuticals, data on file).
Efficacy data
Marinus Pharmaceuticals completed a 10-week phase II clinical trial of ganaxolone (1,500 mg/day) as adjunctive therapy in 147 patients with drug-resistant focal seizures. The results have been reported in the EILAT XII Progress Report 3 and are summarized herein. The primary end point of the study was absolute reduction in seizure frequency over placebo, and this improvement was statistically significant (p = 0.042), with an 18% decrease in mean weekly seizure frequency with ganaxolone versus a 2% increase with placebo (p = 0.014). In a new post hoc analysis, patients who responded to ganaxolone maintained their response over time throughout the 10-week treatment period. In another post hoc analysis, the percentage of ganaxolone-treated patients who achieved ≥40% improvement in weekly seizure frequency was nearly twice that of placebo (30.5% vs. 16.7%; p = 0.07). Significantly more ganaxolone patients achieved ≥30% improvement (43.9% vs. 25.0%; p = 0.027).
We are currently conducting a double-blind, randomized phase III clinical trial in patients with drug-resistant focal seizures using a b.i.d. capsule formulation of ganaxolone at doses of 1,800 mg/day.
Tolerability and adverse effect profile
Safety and tolerability data are based on >1,300 subjects exposed to ganaxolone for periods ranging from 1 day to >2 years at daily doses of 50-2,000 mg/day. Ganaxolone was administered in phase II studies at doses up to 54 mg/ kg in children and up to 1,875 mg/day in adults. Most AEs were mild to moderate and reversible on drug withdrawal, and there have been no treatment-related fatalities. In the ganaxolone safety database there are no trends of clinically important changes in blood chemistry or cardiovascular functions.
In the phase II trial in focal seizures, the most common AEs were dizziness and fatigue, reported by 16% versus 8% for ganaxolone and placebo, respectively, and somnolence (13% for ganaxolone vs. 2% for placebo). Treatment was withdrawn for AEs in 7% of ganaxolone subjects and 6% of placebo subjects. The majority of the AEs in the study were consistent with GABAergic mechanism of action of ganaxolone or the disease.
Planned studies
Marinus Pharmaceuticals is currently evaluating ganaxolone in a phase III study in drug-resistant focal seizures and in two, phase II, proof-of-concept pediatric trials as a treatment for orphan indications including genetic epilepsies and behavior in fragile X syndrome, an autism spectrum disorder. An intravenous formulation of ganaxolone will enter clinical testing for SE in 2016. 
Introduction and rationale for development
Biscayne Pharmaceuticals is a pharmaceutical company focused on the development of compounds for the treatment of neurologic disorders and cancer. Our lead compound is a synthetic form of (-)-huperzine A, a small naturally occurring alkaloid derived from the Chinese club moss Huperzia serrata that has been used in Chinese medicine for hundreds of years to enhance cognitive function and alleviate pain symptoms. 3 In the United States, huperzine A is marketed as a dietary supplement to improve cognitive dysfunction, and has been the target of study in>450 peer-reviewed publications. Extensive animal studies in predictive animal seizure models show that huperzine A (currently in development as BIS-001) displays potent antiseizure effects by enhancing GABAergic tone through presynaptic dependent mechanisms. BIS-001 is a synthetic form of (-)-huperzine A. These findings provide compelling evidence for the clinical development of huperzine A for the treatment of seizure-related disorders.
Pharmacology
Anticonvulsant profile
The antiseizure activity of huperzine A was initially assessed with the assistance of the ASP at the NIH, where huperzine A tested favorably in multiple predictive animal seizure models. 3 Treatment with huperzine A yielded ED 50 values of 0.28, 0.34, and 0.58-0.78 mg/kg in the 6 Hz mouse model at 22, 32, and 44 mA current levels, respectively. 3 Additional testing using our proprietary synthetic form of huperzine A in the 6 Hz (32 mA) yielded a similarly potent effect, with an ED 50 of 0.26 mg/kg. This result supports the efficacy and potency of our proprietary form. Compared to other currently approved AEDs, huperzine A displayed the lowest ED 50 at all current (mA) levels measured. The seizure protection displayed by huperzine A was determined to be cholinergic in nature, as treatment with the muscarinic receptor antagonist atropine was sufficient to eliminate the protective outcome. Administration of huperzine A by the intracerebroventricular (i.c.v.) route yielded a protective index (TD 50 /ED 50 ) of 172. 
Other pharmacologic properties
Huperzine A has been shown previously to be a potent analgesic compound. In the formalin mouse model of acute pain, at doses as low as 0.5 mg/kg (i.p.), huperzine A significantly attenuated the number of flinches by 97% compared to vehicle control during phase I (acute phase), and by 100% in phase II (inflammatory phase). Doses as high as 1 mg/kg eliminated the flinching response during both phases I and II. Huperzine A is also highly successful at attenuating flinching responses after intrathecal delivery. Doses as low as 1, 3, and 10 lg of huperzine A significantly decreased flinching during both phases I and II. 146 Treatment with atropine blocked the analgesic effect of huperzine A in the formalin model, an effect supporting the cholinergic mechanism of action of huperzine A in this model. Additional studies confirmed that huperzine A displays potent antinociceptive capabilities in chronic models of pain. In the rat spinal cord injury model, 50, 167, or 500 lg/kg of huperzine A (i.p.) produced a dose-dependent analgesic effect that persisted for up to 6 h after dosing. 147 Additional studies demonstrated that huperzine A, administered intrathecally, eliminated the chronic hypersensitivity observed following spinal cord injury. The analgesic effect of huperzine A after spinal cord injury was confirmed to be the result of the cholinergic nature of huperzine A, as atropine inhibited huperzine A's analgesic effect in this model. 3 
Mechanism of action
Huperzine A displays potent cholinesterase inhibitor capabilities, with a >900-fold greater specificity for acetylcholinesterase (AChE) over plasma butyrylcholinesterase. 148 This characteristic makes huperzine A more targeted to the CNS than other compounds within the AChE inhibitor class. This effect is confirmed by the fact that huperzine A inhibits AChE activity in multiple brain areas susceptible to seizure manifestation, at doses significantly lower than currently marketed AChE inhibitors. Additional studies conducted with the assistance of the NIH ASP assessing the therapeutic potential of commercially available AChE inhibitory compounds (for example, donepezil), demonstrated that AChE inhibitors as a class display anticonvulsant properties. However, the AChE inhibitors tested, other than huperzine A, provided seizure protection only at doses that resulted in toxicity. Additional studies investigating the seizure protective mechanism of action of huperzine A have demonstrated that activation of cholinergic pathways increases cortical inhibition through the stimulation of GABAergic pathways. 149 The finding that atropine completely prevents the antiseizure and analgesic activity of huperzine A in multiple models clearly suggests that the primary mechanism of action is through AChE inhibition and the GABAergic effect is the secondary effector path of this AChE action. These results in predictive rodent seizure models and models of acute and chronic pain, demonstrate the potent seizure protective and analgesic effects of huperzine A are the result of its CNS-targeted AChE inhibitory mechanism of action. 3 
Toxicology
Chronic toxicology studies have demonstrated that huperzine A displays low toxicity in rats and dogs. Doses up to 1-3 mg/kg in rats and 200 lg/kg in dogs were tolerated with mild or no side effects. Tissue pathology revealed no significant changes in the liver, kidney, heart, lung, or brain of rats (1.5 mg/kg, p.o.) and dogs (0.3 mg/kg, p.o.) treated chronically for >90 days. 3 
Pharmacokinetic and metabolic profile
Pharmacokinetic studies demonstrate a high oral bioavailability and rapid absorption. 3 Following a dose of 10 lg/kg in dogs (n = 5), plasma was analyzed at various time points for time of peak concentration ( t max ), half-life, and bioavailability. Oral absorption of huperzine A was rapid, with a t max of 1.25 h and a bioavailability of 94.4%. 150 Elimination of huperzine A occurred with a mean half-life of 5.71 h. These results coincide with previously published work showing a high oral bioavailability in rats (96%) and halflife of 4.81 h in humans following oral administration. 151, 152 Previous studies in humans investigated the pharmacokinetics of orally administered huperzine A. In one study, administration of a 0.99 mg oral dose was associated with a C max of 8.4 ng/ml, a t max of 1.33 h, and an AUC of 68.3 lgÁh/ml. 151 In another study, 0.4 mg huperzine A orally administered had a C max of 2.59 ng/ml, a t max of 0.97 h, and an AUC of 33.1 lgÁh/ml. 153 The primary route of elimination in mice was excretion in the urine (73%), with a smaller amount detected in feces (2.4%) 24 h after administration. 152 
Drug interactions
In a phase I trial as an add-on therapy to assess the safety and tolerability of huperzine A in patients with refractory epilepsy, doses of 1.6-2.4 mg/day over the course of 4 days had no effect on the plasma concentrations of the commonly used AEDs levetiracetam, lacosamide, carbamazepine, lamotrigine, topiramate, or zonisamide. There have been no additional published studies assessing potential interactions between huperzine A and current AEDs.
Efficacy data
To date, there have been no studies to assess the therapeutic efficacy of huperzine A in patients with epilepsy.
Tolerability and adverse effect profile
In a phase I trial, huperzine A at doses of 1.6-2.4 mg/day demonstrated dose-dependent AEs typical of cholinergic medications. Specifically, patients presented with nausea and vomiting thought to be due to the rapid absorption of the current immediate release form. Digital Holter monitoring was used to assess cardiovascular function throughout the trial. In all patients, QTc interval remained unaltered, and improvement in patients with abnormal ECG patterns (i.e., T-wave alterations, atrioventricular block, and abnormal sinus rhythm) was observed following treatment with huperzine A. 3 In general, administration of huperzine A did not alter cardiac electrical activity. During a clinical study in patients diagnosed with Alzheimer's disease, doses of 400 lg, b.i.d., huperzine A were generally well tolerated. During the trial, the most prevalent AEs were cholinergic in nature, i.e., nausea and vomiting. 154 
Planned studies
Biscayne Pharmaceuticals is developing an extended release formulation of huperzine A appropriate for small children and adults to reduce C max -related side effects and to slow the elimination phase, which implies the need for 4-6 times daily dosing with the current immediate release formulation. Preformulation studies identifying biophysical properties of the molecule predict a straightforward development path. Initial prototype development has shown a 99% drug load and a markedly reduced C max and slowed drug clearance. This formulation will be used in a pilot study in children with Dravet syndrome, as well as in a Phase II study in adults with refractory complex partial seizures.
Minocycline
Sookyong Koh Children's Healthcare of Atlanta and Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, U.S.A.
Introduction and rationale for development
Among the tetracycline class of antibiotics, minocycline is highly brain penetrant and possesses antiinflammatory, immunomodulatory, and antiapoptotic properties. Because of these properties, minocycline has been considered as a potential epilepsy therapeutic by targeting pathologic mechanisms believed to contribute to disease progression in epilepsy.
Pharmacology
Anticonvulsant profile
The anticonvulsant profile of minocycline has been described previously. 3 Minocycline has been shown to be effective in the 6-Hz seizure model, 155 and to modify the expression of amygdala-kindled seizures. 156 
Other pharmacologic properties
In addition to its ability to attenuate the "second hit" phenomena in animals previously exposed to kainic acid-induced SE in early life, minocycline's antiinflammatory actions are thought to be important to its ability to attenuate the long-term damaging effects of early life seizures when administered post-SE 157 Moreover, an o.d. dose (45 mg/kg) given for 14 days post-SE in adult animals selectively inhibited SE-induced microglia activation and neuronal loss, and reduced the frequency, duration, and severity of spontaneous recurrent seizures in the lithium-pilocarpine rat model of temporal lobe epilepsy. 158 
Mechanism of action
The mechanism of action of minocycline has been described previously. 3 Briefly, in addition to an ability to inhibit mitochondrial cytochrome-c release, minocycline blocks death receptor pathways and activation of microglia. Minocycline exerts antiinflammatory effects by decreasing a number of processes that contribute to the immune response including NF-kappaB activation, lipopolysaccharide (LPS)-stimulated LOX-1 (lectin-like oxidized low density lipoprotein receptor-1), LITAF (LPS-induced tumor necrosis factor [TNF]-a), Nur77 pathways, p38 MAPK (mitogen-activated protein kinase), and PI3K/Akt (phosphoinositide 3-kinase/Akt) pathway.
immunologic response by interacting with matrix metalloproteinase (MMPs), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) attenuating CD4 (+) -cell activation, and by modulating microglia T-cell interaction. 3 By inhibiting points of convergence of various signaling pathways that mediate multiple distinct and interacting inflammatory signals, minocycline may influence monocyte activation, traffic, and recruitment into the brain. These and perhaps other actions may contribute to the neuroprotective properties reported in models of stroke, TBI, HIV CNS disease, encephalomyelitis, Huntington's disease, Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis.
Toxicology
The toxicology of minocycline is summarized in the EILAT XII Progress Report. 3 
Pharmacokinetic and metabolic profile
As summarized in the EILAT XII Progress Report, 3 minocycline is absorbed rapidly from the gastrointestinal tract, crosses readily the blood-brain barrier, and is excreted primarily by the kidney. The half-life of minocycline is in the order of 11-13 h.
Drug interactions
Minocycline can interact with oral contraceptives, oral anticoagulants, digoxin, methoxyflurane, and several other drugs. For more information, the reader is referred to the EILAT XII Progress Report. 3 
Efficacy data
In a placebo-controlled, double-blind trial conducted in 12 healthy human volunteers, a single oral dose of minocycline (200 mg) was found to reduce cerebral cortex excitability, as assessed by changes in the response to transcranial magnetic stimulation. 159 An open-label trial of minocycline in children with Angelman syndrome established that minocycline at a dose of 3 mg/kg, up to 200 mg/day, was well tolerated and associated with significantly improved communication and adaptive behaviors such as fine motor ability and self-direction. 160 Similarly, short-term treatment with minocycline was reported to be associated with improved communication and attention, and reduced anxiety in young adults with fragile X syndrome. 161 These studies raise a possibility of future use of minocycline as a potential disease-modifying agent not only to block epileptogenesis, but also to ameliorate neuropsychiatric comorbidities in pediatric epilepsy.
Tolerability and adverse effect profile
The tolerability and AE profile of minocycline are described in the EILAT XII Progress Report. 3 
Planned studies
Two currently active studies were identified in Clinica lTrials.gov and Ema.Europa.eu. A phase I dose-escalation study (I NCT01058395) is aimed at exploring the safety and efficacy of minocycline in moderate and severe TBI. A phase II open-label study evaluating the effects of minocycline in children with Angelman syndrome (II NCT02056665) is also ongoing.
NAX 810-2
Introduction and rationale for development Galanin is one of several known anticonvulsant peptides, 162, 163 and both its major receptor subtypes, GalR1 and GalR2, play a role in seizures. [164] [165] [166] [167] The development of a systemic formulation of the native peptide galanin has been hindered by poor metabolic stability and lack of bloodbrain barrier penetration, and activation of GalR1 inhibits insulin release. [168] [169] [170] Since the initial characterization of the lead GalR2-preferring analog, NAX 810-2, in a variety of animal models, 2,3 additional studies have been performed using an intravenous formulation in mice, which is the anticipated route of administration in clinical proof-of-concept studies.
Pharmacology
NAX 810-2 is a GalR2-preferring agonist with both anticonvulsant and analgesic properties. The antiseizure activity of NAX 810-2 has been described previously. 2, 3 More recently, NAX 810-2 has been found to potently protect against seizures in the mouse 32 mA 6 Hz seizure and corneal kindling models following intravenous administration, with ED 50 values of 1.1 and 1.8 mg/kg respectively.
A broad receptor screening study has yielded potential activity at the urotensin II, alpha 2C adrenergic, and angiotensin I receptors. NAX 810-2 also demonstrated potential enhancement of HCN4 ion channel currents. The significance of these observations as it relates to preclinical anticonvulsant efficacy and tolerability is unknown.
Toxicology
The GalR2-preferring analog NAX 810-2 does not elevate blood glucose levels at anticonvulsant doses, whereas the GalR1-preferring compound NAX 505-5 can block glucose-stimulated insulin release in the glucose tolerance test and elevate glucose levels.
Pharmacokinetic and metabolic profile
NAX 810-2 is highly plasma protein bound (>99%) and shows linear pharmacokinetics following intravenous administration in mice. In mice, clearance was estimated to be 0.4 L/h and half-life was 1.2 h. Additional safety and pharmacokinetic studies following intravenous infusion in rats and nonhuman primates demonstrated dose-dependent increases in C max at approximately 1 h following infusion onset. The estimated half-life in rats following intraperitoneal bolus administration is approximately 2 h. CYP inhibition studies in human hepatocytes did not identify any significant interactions that would be suggestive of a liability for drug-drug interactions.
Planned studies
Ongoing studies include ***IND-enabling studies in rats and nonhuman primates.
1OP-2198
Christopher Crean and Geoffrey Banks 1st Order Pharmaceuticals, Research Triangle Park, North Carolina, U.S.A.
Introduction and rationale for development
1OP-2198 is a highly selective, second generation, opener of neuronal Kv7 (KCNQ) potassium channels, the molecular component of the slow activating/deactivating voltage-gated M-current. 1OP-2198 exhibits selectivity of >100-fold against other ion channels and receptors and is devoid of GABAergic activity.
Toxicology
The nonclinical Investigational New Drug (IND) enabling toxicology package of studies, including 28-day oral toxicity in rats and cynomolgus monkey, based on International Conference on Harmonization (ICH) guidelines in support of oral administration, is completed and has demonstrated adequate safety to start clinical trials. There were no significant remarkable effects after single administration in the rat CNS pharmacology tests at 70-fold dose margins over the ED 50 MES model dose. There were no significant effects on renal function at a 30-fold dose margin in the rat renal pharmacology model over the MES ED 50 dose. In the 28-day monkey study, expected findings were CNS adverse effects, which were mild/moderate in severity within the high-dose group, 10 mg/kg. There were no observable adverse effects on cardiovascular safety at the highest dose evaluated in the monkey, and there were no signs of genotoxicity.
Pharmacokinetic and metabolic profile
The pharmacokinetics of oral 1OP-2198 have been evaluated in rats and monkeys. In rats given 1OP-2198, i.v., the mean half-life is 5.4 h and plasma clearance is 12.5% of hepatic blood flow. After a single oral dose of 10 mg/kg, the mean half-life is similar to that found after intravenous dosing, C max is 1.1 lM, and AUC is 11 hÁlM. In monkeys, the mean half-life after intravenous administration is 7.8 h and plasma clearance is 25.7% of hepatic blood flow. After a single oral dose of 1 mg/kg, the mean half-life is 11.5 h, t max occurs at 2.2 h, and C max and AUC 0-∞ are 127 nM and 0.915 lMÁh, respectively. In monkeys, C max is less than dose proportional, whereas AUC is dose proportional. After a 10 mg/kg oral dose in monkeys, C max is 600 nM, t max is 4 h, half-life is 18.5 h, and AUC 0-∞ is 12.5 lMÁh. The monkey was selected as the nonrodent toxicology species due to similarities of the in vitro radiolabeled metabolite profile compared with that found in human hepatocyte incubations.
At the end of the incubation in human hepatocytes, >90% of 1OP-2198 remained in the incubates, whereas 1OP-2198 was <80% in rat, dog, and monkey incubates. 1OP-2198 is a chemical class separate from the first generation Kv7 channel openers and thus will not form the retigabine-retigabine dimers implicated in the discoloration of skin, lips, and nails or the possible retinal pigmentary changes.
Drug interactions
Studies of regulatory guidance-defined in vitro hepatic drug-interaction and enzyme-induction have not been conducted. 1OP-2198 at concentrations up to 3 lM did not inhibit recombinant expressed CYP enzymes in a non-GLP assay. An in vitro permeability assay based on the MDR1-MDCK cell line demonstrated that 1OP-2198 has high A-B and B-A permeability and an efflux ratio <1, which suggests high brain penetration.
Planned studies
To date, no human studies have been initiated with 1OP-2198. The first-in-human trial will be a single ascending dose trial with an immediate release formulation in healthy male and female volunteers, with an anticipated starting dose of 5 mg. The trial will evaluate the single dose pharmacokinetics and tolerability of 1OP-2198 up to a maximum tolerated dose. To support clinical trials in males and females longer than 4 weeks in duration, 1OP will perform subchronic (3-month) studies in rats and monkeys and segment II reproductive toxicology studies in rats and rabbits. To advance into pediatric clinical trials, 1OP anticipates the need to complete rat juvenile toxicology studies of appropriate duration to provide toxicology coverage for the clinical trial length after initial safety and efficacy data in adults have been collected.
Introduction and rationale for development
SAGE-217 is a next-generation neuroactive steroid that acts as a positive allosteric modulator of representative synaptic and extrasynaptic GABA A receptors. As described previously and summarized below (see Bialer et al., 3 for review and references), SAGE-217 exhibits antiseizure activity in preclinical rodent seizure models and models of SE. SAGE-217 has completed phase I single and multiple ascending dose studies in June 2016.
Pharmacology
Anticonvulsant profile
The anticonvulsant activity of SAGE-217 has been demonstrated in a range of preclinical models, including the mouse PTZ seizure model, the mouse 6 Hz electrical stimulation seizure model, the rat lithium-pilocarpine model of SE, the mouse MTLE model, and the mouse MES model. 3 These preclinical models have shown efficacy of SAGE-217 at nanomolar plasma concentrations, and demonstrated its potential for further development as an antiepileptic therapeutic.
In addition, pharmaco-EEG studies have been conducted with intravenous and oral dosing preclinically and with oral dosing in clinical studies. Systemic administration of SAGE-217 produces concentration-dependent changes in spectral EEG power in the beta-frequency (12.5-30 Hz) range, similar to other neuroactive steroids. 175 As detailed previously, SAGE-217 exhibits limited secondary pharmacology in a broad array of in vitro and functional assays. 
Toxicology
A battery of IND-enabling toxicology and safety pharmacology studies (14-day general toxicology studies in rats and dogs; a genotoxicity battery of Ames, rat micronucleus, and Comet assays; and a safety pharmacology battery of rat CNS, rat respiratory, and dog telemetry studies) required for entry into phase I clinical studies have been completed.
Pharmacokinetic and metabolic profile
The pharmacokinetic profile of SAGE-217 obtained in phase I single and multiple ascending dose studies is consistent with once daily oral dosing, with dose linearity over the multiple dose range studied (0.25-66 mg single doses, 15-35 mg multiple doses) and a half-life ranging from 10 to 25 h. In the multiple dose study, there was a slight SAGE-217 accumulation commensurate with the long half-life of the drug. Based on the half-life, steady-state serum concentration was estimated to be achieved in 4-5 days. Worthy of note, a reduction in C max was observed in fed versus fasting state, albeit in a small arm of the study, suggesting the potential ability to favorably affect dosing by administration with food.
Drug interactions
No formal drug interaction studies have been conducted for SAGE-217 to date. In vitro CYP inhibition studies showed half maximal inhibitory concentration (IC 50 ) values >30 lM for all major isozymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2B6, and CYP3A4). Low levels of induction of CYP3A4 and CYP2B6 were observed in enzyme induction studies conducted in human cultures of primary hepatocytes.
Human pharmacodynamic data
In a phase I double-blind single ascending dose study in 72 healthy volunteers randomized to SAGE-217 or placebo in a 3:1 ratio, SAGE-217 was administered as an oral solution at doses between 0.25 and 66 mg in nine cohorts of subjects. Similarly, in a phase I double-blind multiple ascending dose study, four cohorts were randomized in a 3:1 ratio to SAGE-217 or placebo, with oral doses of 15 mg, 30 mg (morning and evening cohorts), and 35 mg being tested against placebo over 7 days in 36 healthy volunteers. EEG recordings used to assess cerebral electrical activity showed clear evidence of target engagement (GABA A -receptor modulation) starting at the lowest dose tested (15 mg) in the multiple dose portion of the study. Throughout the 7-day dosing period, the observed EEG effect showed no evidence for tachyphylaxis, and a slight increase in the EEG response was observed across days consistent with accumulated drug exposures.
Tolerability and adverse effect profile
In the single and multiple ascending dose studies, SAGE-217 doses were escalated until the maximum tolerated dose was achieved based on prespecified stopping criteria, which included observation of a serious or severe AE, onset of deep sedation (e.g., a Modified Observer's Assessment of Alertness/Sedation Scale [MOAA/S] of ≤2, with a confirmed repeat score of ≤2 in one subject or two or more SAGE-217-exposed subjects with a confirmed MOAA/S score of ≤3), and alterations of other measurements related to chemistry or hematology.
Most AEs were reported as mild or moderate in intensity. No serious AEs were reported in either study. Based on the prespecified stopping criteria, the maximal tolerated dose was established at 55 mg in the single ascending dose study and at 30 mg/day in the multiple ascending dose study. In both cases, the stopping criteria were triggered by the onset of deep sedation (MOAA/S scores of ≤2, with a confirmed repeat score of ≤2). Overall, the rates of moderate to deep sedation were comparable to placebo until the maximum tolerated dose was reached, in both the single and multiple ascending dose phases of the study.
The effects of SAGE-217 administration on cognition were also examined in the multiple ascending dose study on days 1 and 7. Psychomotor function, attention, visual learning, and executive function were evaluated, and no significant effect on cognition was observed in the 15-and 30-mg-dosed patients.
Planned studies
Planned future activities for SAGE-217 include all necessary studies required to advance into later stage clinical trials. This includes, and is not limited to, subchronic (3-month) and chronic (6 or 9-month) studies in rats and dogs, reproductive toxicology studies in rats and rabbits, a battery of abuse liability of drug dependence, drug discrimination and self-administration, and carcinogenicity studies in rats and mice.
A phase II clinical program is also planned to evaluate SAGE-217 in essential tremor and other indications.
Introduction and rationale for development
SAGE-689 is a next-generation neuroactive steroid acting as a potent and highly selective positive allosteric modulator of the GABA A receptor. It is a short-acting, parenteral agent with a wide therapeutic window. SAGE-689 is being developed as an adjunctive intravenous therapy for the treatment of SE in patients whose seizures have not resolved after treatment with traditional therapies (i.e., benzodiazepines). 13 
Pharmacology
Anticonvulsant profile
In the lithium-pilocarpine-induced SE model, SAGE-689 (15 mg/kg, i.v.) halted seizures in rats when administered at 60 min following the onset of SE. In contrast, diazepam (10 mg/kg, i.v.) failed to halt SE when administered 60 min following SE onset.
Mechanism of action
SAGE-689 is a selective positive allosteric modulator of synaptic and extrasynaptic GABA A receptors. In electrophysiologic recordings from recombinantly expressed human GABA A receptors in vitro, SAGE-689 potentiated receptor function with an E max value of 1,067% and an EC 50 value of 1,077 nM at a 1 b 2 c 2 receptors and an E max of 715% and an EC 50 
Toxicology
SAGE-689 has completed preclinical IND-enabling toxicology and safety pharmacology studies.
Pharmacokinetic and metabolic profile
SAGE-689 has not been administered to human subjects to date, so no human pharmacokinetic data are available. Estimates of human clearance predicted from nonclinical in vivo and in vitro data are 0.73-1.24 L/h/kg, respectively. In vitro metabolic profiling was conducted in cryopreserved human, rat, and dog hepatocytes, and revealed essentially five discrete metabolites. Although structural identification of these metabolites has not been conducted to date, their molecular mass suggests that they consist of dehydrogenation and/or hydroxylated metabolites with subsequent glucuronidation products observed.
Drug interactions
Although no formal drug interaction studies have been conducted, in vitro CYP inhibition studies showed IC 50 values >40 lM for CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2B6, and CYP3A4, suggesting low potential for SAGE-689 to inhibit the metabolism of substrates for those enzymes. SAGE-689 was found to be a potent inhibitor of CYP2C8, and has the potential to alter the pharmacokinetics of substrates for this enzyme.
Efficacy, tolerability, and adverse effect profile To date, no human studies have been completed with SAGE-689.
Planned studies
SAGE-689 has completed preclinical IND-enabling toxicology and safety pharmacology studies to support a phase I clinical development program.
Introduction
sec-Butylpropylacetamide is a one-carbon homologue of valnoctamide, a chiral constitutional isomer of valpromide (VPD), which is valproic acid's corresponding amide. Racemic-sec-butylpropylacetamide and racemic-valnoctamide possess a unique and broad-spectrum antiseizure profile superior to that of valproic acid. In addition, sec-butylpropylacetamide blocks behavioral and electrographic SE induced by pilocarpine and the organophosphates soman and paraoxon. Valnoctamide has activity similar to that of sec-butylpropylacetamide in the soman-induced SE model, but is less active in the pilocarpine-induced SE model. The activity of sec-butylpropylacetamide and valnoctamide against SE is superior to that of diazepam and midazolam in terms of rapid onset, potency, and ability to block SE when given intraperitoneally 20-60 min after seizure onset.
sec-Butylpropylacetamide and valnoctamide possess two stereogenic carbons in their chemical structure, and exhibit stereoselective pharmacokinetics in humans (valnoctamide) and animals, and thus exist as racemic mixtures of four individual stereoisomers. 3, 176 Recently, a pharmacokinetic/ pharmacodynamic analysis was conducted on two constitutional isomers of sec-butylpropylacetamide and one of valnoctamide, and none of them was found to be superior to the parent compound(s). 177 Since the EILAT XII Progress Report, 3 new results have been accomplished with valnoctamide and sec-butylpropylacetamide, as detailed below.
Pharmacology and toxicology of valnoctamide
Anticonvulsant profile in SE
In the rat pilocarpine-induced SE model, valnoctamide was active only at a dose of 180 mg/kg, i.p., when administered 30 min after seizure onset, whereas sec-butylpropylacetamide and its individual stereoisomers stopped SE seizures at lower ED 50 values of 95-135 mg/kg, i.p. 176, 178, 179 In contrast, in the soman-induced SE model, valnoctamide was equipotent to sec-butylpropylacetamide. 178, 180 All four valnoctamide individual stereoisomers demonstrated anticonvulsant activity when given intraperitoneally 20 min after seizure onset to rats in the soman-induced SE model, and their ED 50 
Teratogenicity
A comparative teratogenicity study of valnoctamide and two of the most commonly used drugs to treat bipolar disorder-risperidone and olanzapine-was carried out in a mouse model system. Pregnant dams were treated with the aforementioned three drugs at the dose levels calculated as an equal proportion of the drugs' respective median lethal dose (LD 50 ) value. Main reproductive indices examined included numbers of implantations and resorptions, and viable and dead fetuses; fetal gross, visceral, and skeletal abnormalities were also assessed. The outcomes of this study indicated that olanzapine was the most teratogenic of the three drugs, inducing maternal, embryo-, and fetotoxicity. Risperidone also exerted significant prenatal toxicity, which was, however, less pronounced than that induced by olanzapine. Valnoctamide did not show any teratogenic effect even when used at relatively higher dosages than olanzapine and risperidone. In conclusion, under the above experimental conditions, valnoctamide demonstrated the lowest prenatal toxicity of the three tested drugs. 181 Pharmacology of sec-butylpropylacetamide
Anticonvulsant profile in SE
Recently, the activity of sec-butylpropylacetamide and two of its individual stereoisomers, (2S,3S)-sec-butylpropylacetamide and (2R,3R)-sec-butylpropylacetamide, was investigated in the paraoxon-induced SE model 182 All rats were provided with antidotal treatment with atropine and toxogonin. Epileptic activity was measured using a novel automated system in order to evaluate the different effects of midazolam, sec-butylpropylacetamide, and its individual stereoisomers in comparison to nontreated controls. Treatment with sec-butylpropylacetamide or its individual stereoisomer (2S,3S)-sec-butylpropylacetamide (i.m.), significantly shortened paraoxon-induced SE and reduced the duration of recorded pathological activity after the SE was terminated. (2S,3S)-sec-Butylpropylacetamide was superior to racemic sec-butylpropylacetamide in diminishing delayed pathologic epileptiform activity within the first 8 h after SE. 182 These results suggest that sec-butylpropylacetamide is an efficient drug for the rapid termination of SE and pathologic epileptiform activity following paraoxon poisoning, which could prevent post-SE neuronal dysfunction and epilepsy development.
Other pharmacologic properties
In a recent study, sec-butylpropylacetamide's antinociceptive potential was evaluated in neuropathic and acute inflammatory pain models. sec-Butylpropylacetamide, given by the intraperitoneal route, was evaluated in the formalin, carrageenan, and writhing tests, and showed potency either higher or equal to that of valproic acid. The ability of sec-butylpropylacetamide to modify compound action potentials was evaluated in a rat peripheral sciatic nerve preparation using a modified sucrose-gap recording, where it showed no effects on compound action potentials properties. 183 sec-Butylpropylacetamide's anti-migraine potential after intraperitoneal administration was evaluated in the cortical spreading depression and nitroglycerin models of migraine. In the cortical spreading depression model, the sec-butylpropylacetamide-treated group showed a significantly lower median number of cortical spreading depressions compared with controls. In the nitroglycerin-induced mechanical allodynia model, sec-butylpropylacetamide dose-dependently reduced mechanical sensitivity compared with controls. These results show sec-butylpropylacetamide's potential as a promising novel antimigraine compound, and suggest a GABAergic mechanism of action. Mechanisms of action sec-Butylpropylacetamide's mechanism of action was studied in a whole-cell recordings performed on cultured cortical neurons and neuroblastoma cells. At a concentration of 0.3-0.5 mM, sec-butylpropylacetamide showed both a significant potentiation of GABA-mediated currents and a smaller but significant decrease in N-methyl-D-aspartate (NMDA) currents in cultured cortical neurons. Kainic acidevoked currents and voltage-dependent sodium channel currents were not changed by sec-butylpropylacetamide.
183,184
Spampanato and Dudek 185 recently showed that racemic valnoctamide acts directly on the GABA A receptors comparable to the effects of benzodiazepines; however, valnoctamide's effect persisted in the presence of the benzodiazepine-binding site antagonist flumazenil and was additive to the effect of diazepam. These findings may also apply to sec-butylpropylacetamide. However, the lack of significant differences between sec-butylpropylacetamide and valnoctamide and their individual stereoisomers suggests that their unique activity in three benzodiazepine-resistant SE models and broad anticonvulsant activity is due to multiple mechanisms of action in addition to the above activity on the GABA A receptors.
Pharmacokinetics and pharmacodynamics of secbutylpropylacetamide after different routes of administration All sec-butylpropylacetamide anticonvulsant data, with the exception of the paraoxon model, have been obtained after intraperitoneal administration. Because intraperitoneal administration is hardly applicable to humans, further experiments in rats were conducted after intramuscular dosing, which is a route of administration commonly used clinically and is considered as a "mass-causality friendly" route for medical countermeasures to be used in the initial treatment of exposures to chemical threats. Specifically, a comparative pharmacokinetic/pharmacodynamic analysis of sec-butylpropylacetamide was conducted following intraperitoneal, intramuscular, and intravenous administration to rats, including estimating sec-butylpropylacetamide's absolute bioavailability following the two routes of extravascular administration.
The absolute bioavailability of sec-butylpropylacetamide following intraperitoneal and intramuscular administration was 76% and 96%, respectively, and its clearance and halflife were 1.8-2.5 L/h/kg and 1.5-1.7 h, respectively. secButylpropylacetamide's brain-to-plasma-AUC ratio after the various routes of administration was 1.86 (i.v.), 0.77 (i.m.), and 2.31 (i.p.). 186 Despite the incomplete intraperitoneal bioavailability (76%) and a reduced brain-to-plasma ratio after intramuscular dosing, ED 50 values of sec-butylpropylacetamide and its individual stereoisomers when given at 30 min after SE onset were almost identical following intraperitoneal and intramuscular administration to rats. 188 The lower brain-to-plasma ratio of sec-butylpropylacetamide after intramuscular administration may be due to a slower absorption rate of the compound compared with the intraperitoneal route. The brain-to-plasma ratio of valproic acid, valnoctamide, and VPD in rats is 0.16, 1.0, and 1.0, respectively. Thus, sec-butylpropylacetamide's brain-toplasma ratio is 12 times higher than that of valproic acid and twice as high as that of valnoctamide and VPD. sec-Butylpropylacetamide's higher brain permeability may be one of the reasons for its better anticonvulsant potency compared with valproic acid and valnoctamide in the pilocarpine SE model. 186 Although sec-butylpropylacetamide's protective index (TD 50 /ED 50 ) in the pilocarpine SE model is <1, for a serious life-threatening condition such as refractory SE, it is extremely important that convulsive seizures be controlled as quickly as feasible, as "time is brain." The finding that secbutylpropylacetamide is effective against benzodiazepineresistant SE in the pilocarpine and the soman models suggests that sec-butylpropylacetamide could be a valuable alternative to currently available "standards of care." As shown in previous work, 187 sec-butylpropylacetamide does indeed preserve long-term cognitive function and reduces neuronal damage as measured by FluorJade B staining in animal models.
Planned studies
Valproic acid is a frequently prescribed AED, but its clinical use is restricted in women of childbearing age due to teratogenicity. 188 The development of sec-butylpropylacetamide and/or valnoctamide as new potentially nonteratogenic broad-spectrum AEDs that are more potent than valproic acid and benzodiazepines (in SE models), may lead to a follow-up compound to valproic acid that is suitable for women of childbearing age as well as therapy-resistant patients with epilepsy. 189 Consequently, sec-butylpropylacetamide and its individual stereoisomers are currently being evaluated in the tetramethylenedisulfotetramine (TETS)-induced SE model, and the recently developed secbutylpropylacetamide intramuscular formulation is being modified to enhance brain penetration. In addition, secbutylpropylacetamide and valnoctamide neuroprotective properties will be investigated.
Conclusions
Despite the introduction of >20 second-generation AEDs during the past three decades, about one third of people with epilepsy continue to be resistant to available pharmacologic treatments. Therefore, the need to develop newer and moreeffective AEDs remains a top priority in epilepsy research. The results summarized in the present progress report demonstrate that considerable efforts are still ongoing into the discovery and development of novel medications for epilepsy. Of the compounds or classes of compounds discussed in this report, one already received marketing approval shortly before the Conference (brivaracetam), 12 are in phase I to III clinical development (adenosine, allopregnanolone, bumetanide, cannabidiol, cannabidivarin, 2-deoxy-D-glucose, everolimus, fenfluramine, huperzine A, minocycline, SAGE-217, and valnoctamide), and 6 are still at the stage of preclinical investigation (bumetanide derivatives, sec-butylpropylacetamide, FV-082, 1OP-2198, NAX 810-2, and SAGE-689). Many of these compounds show innovative mechanisms of action, and for many, preliminary clinical data are already available, suggesting usefulness in a variety of epilepsy syndromes, including some previously neglected orphan conditions.
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